The Serum and Glucocorticoid inducible Kinase in the regulation of sodium coupled amino acid transporters

von
Jeyaganesh Rajamanickam
aus Madurai, Indien
vorgelegte
Dissertation
2007
Tag der mündlichen Prüfung: 07.03.2007
Dekan: Prof. Dr. Friedrich Schöffl
1. Berichterstatter: Prof. Dr. Florian Lang
2. Berichterstatter: Prof. Dr. Fritz Götz
CONTENTS

ABBREVIATIONS ......................................................................................................................................... 1

1 ZUSAMMENFASSUNG .............................................................................................................................. 3

2 SUMMARY .................................................................................................................................................. 6

3 INTRODUCTION ......................................................................................................................................... 9
  3.1 THE SERUM AND GLUCOCORTICOID INDUCIBLE KINASE SGK1 ............................................................... 9
  3.2 THE PROTEIN KINASE B .......................................................................................................................... 13
  3.3 THE UBIQUITIN LIGASE NEDD4-2 ............................................................................................................. 16
  3.4 GLUTAMATERGIC NEUROTRANSMISSION .............................................................................................. 20
    3.4.1 Excitatory Amino Acid Transporters (EAATs) ...................................................................................... 23
    3.4.2 The Excitatory Amino Acid Transporter 2 (EAAT2) ........................................................................... 25
    3.4.2.1 The Excitatory Amino Acid Transporter 4 (EAAT4) ..................................................................... 26

4 AIM OF THE STUDY .................................................................................................................................... 28

5 MATERIALS AND METHODS .................................................................................................................. 30
  5.1 SITE DIRECTED MUTAGENESIS ............................................................................................................ 30
    5.1.1 Transformation of E.coli XL1-Blue Supercompetent Cells ....................................................................... 34
  5.2 PREPARATION OF CRNA ....................................................................................................................... 34
    5.2.1 Plasmid DNA linearization ................................................................................................................... 35
    5.2.2 cRNA synthesis .................................................................................................................................. 36
  5.3 XENOPUS LAEVIS OOCYTE PREPARATION ......................................................................................... 37
  5.4 PROTEIN EXPRESSION IN XENOPUS LAEVIS OOCYES ...................................................................... 39
  5.5 NEDD4-2 RNA SILENCING BY siRNA .................................................................................................... 40
  5.6 TRACER FLUX MEASUREMENTS .......................................................................................................... 41
  5.7 DETECTION OF CELL SURFACE EXPRESSION BY CHEMILUMINESCENCE ........................................... 42
  5.8 WESTERN BLOTTING ............................................................................................................................. 44
  5.9 STATISTICAL ANALYSIS ...................................................................................................................... 45

6 RESULTS .................................................................................................................................................... 46
  6.1 MODULATION OF EAAT2 BY SGK1-3 AND PKB .................................................................................. 46
    6.1.1 SGK1 stimulates EAAT2 activity and plasma membrane abundance .................................................. 46
    6.1.2 SGK1 isoforms SGK2-3 and PKB similarly stimulate Nedd4-2 plasma membrane abundance .... 47
    6.1.3 SGK1 enhances EAAT2 by inhibiting Nedd4-2 effects without altering Nedd4-2 expression ....... 49
  6.2 MODULATION OF EAAT4 BY SGK1 ....................................................................................................... 53
    6.2.1 SGK1 enhances EAAT4 mediated glutamate transport ........................................................................ 53
    6.2.2 Disruption of the putative SGK1 phosphorylation sites (Thr40 and Thr504) on EAAT4 abrogates transporter stimulation .............................................................................................................. 54
    6.2.3 Phosphorylation at Thr40 on EAAT4 is essential for transporter stimulation .................................. 56
    6.2.4 Phosphorylation at Thr40 on EAAT4 is required for enhanced EAAT4 plasma membrane abundance .............................................................................................................................................................................. 58
    6.2.5 Nedd4-2 coexpression inhibits the activity of EAAT4 ........................................................................ 59
    6.2.6 Silencing of intrinsic xNedd4-2 upregulates EAAT4 function ............................................................. 60
      6.2.6.1 xNedd4-2 siRNA downregulates xNedd4-2 expression ................................................................. 62
      6.2.6.2 xNedd4-2 siRNA does not alter GLUT1 expression ................................................................. 62

7 DISCUSSION ............................................................................................................................................. 64

8 REFERENCES ............................................................................................................................................. 68

ACKNOWLEDGEMENT ............................................................................................................................. 89

CURRICULUM VITAE ................................................................................................................................. 90
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>2-DOG</td>
<td>2-deoxy-D-glucose</td>
</tr>
<tr>
<td>AMPA</td>
<td>α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid</td>
</tr>
<tr>
<td>ALS</td>
<td>Amyotrophic lateral sclerosis</td>
</tr>
<tr>
<td>ATP</td>
<td>Adenosine triphosphate</td>
</tr>
<tr>
<td>BSA</td>
<td>Bovine serum albumin</td>
</tr>
<tr>
<td>cAMP</td>
<td>Cyclic adenosine monophosphate</td>
</tr>
<tr>
<td>CNS</td>
<td>Central nervous system</td>
</tr>
<tr>
<td>cRNA</td>
<td>Complementary ribonucleic acid</td>
</tr>
<tr>
<td>EAATs</td>
<td>Excitatory amino acid transporters</td>
</tr>
<tr>
<td>EGFR</td>
<td>Epidermal growth factor receptor</td>
</tr>
<tr>
<td>ENaC</td>
<td>Epithelial sodium channel</td>
</tr>
<tr>
<td>FSH</td>
<td>Follicle stimulating hormone</td>
</tr>
<tr>
<td>Gln</td>
<td>Glutamine</td>
</tr>
<tr>
<td>Glu</td>
<td>Glutamate</td>
</tr>
<tr>
<td>GLUT1</td>
<td>Glucose transporter1</td>
</tr>
<tr>
<td>HA</td>
<td>Haemagglutinin</td>
</tr>
<tr>
<td>HECT</td>
<td>Homologous to E6AP-carboxyl-terminus</td>
</tr>
<tr>
<td>HEK293</td>
<td>Human embryonic kidney cells 293</td>
</tr>
<tr>
<td>HEPES</td>
<td>4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid</td>
</tr>
<tr>
<td>IGF-1</td>
<td>Insulin-like growth factor-1</td>
</tr>
<tr>
<td>Nedd4-2</td>
<td>Neuronal cell expressed developmentally downregulated 4-2</td>
</tr>
<tr>
<td>NMDA</td>
<td>N-methyl-D-aspartate</td>
</tr>
<tr>
<td>PBS</td>
<td>Phosphate buffered saline</td>
</tr>
<tr>
<td>PCR</td>
<td>Polymerase chain reaction</td>
</tr>
<tr>
<td>PDGF</td>
<td>Platelet derived growth factor</td>
</tr>
<tr>
<td>PDK</td>
<td>3-phosphoinositide-dependent protein kinase</td>
</tr>
<tr>
<td>PI3K</td>
<td>Phosphatidylinositol 3-kinase</td>
</tr>
<tr>
<td>PKB</td>
<td>Protein kinase B</td>
</tr>
<tr>
<td>RISC</td>
<td>RNA induced silencing complex</td>
</tr>
<tr>
<td>RLU</td>
<td>Relative light units</td>
</tr>
<tr>
<td>ROMK1</td>
<td>Renal outer medullary potassium channel</td>
</tr>
<tr>
<td>Ser</td>
<td>Serine</td>
</tr>
<tr>
<td>SGK</td>
<td>Serum and glucocorticoid inducible protein kinase</td>
</tr>
</tbody>
</table>
siRNA       Short interference ribonucleic acid
TGF- β      Transforming growth factor-β
Thr         Threonine
TM          Transmembrane domain
VGLUT       Vesicular glutamate transporter
1 Zusammenfassung


Der natriumgekoppelte exzitatorische Aminosäuretransporter EAAT2 ist der wichtigste Glutamattransporter im zentralen Nervensystem der höheren Vertebraten. EAAT2 hält die extrazelluläre Konzentration des Glutamats unter toxischem Niveau. Eine gestörte Expression des Transporters führt zu Exzitotoxizität und trägt möglicherweise zu Krankheiten wie etwa der amyotrophischen lateralen Sklerose (ALS) bei. SGK1 ist im Gehirn exprimiert, interagiert dort mit der Ubiquitinligase Nedd4-2 und moduliert Membrantransporter und Ionenkanäle. Die vorliegende Studie untersucht ob SGK1 und ihre Isoformen SGK2 und 3 sowie die Proteinkinase B (PKB) EAAT2 regulieren.

Dazu wurde die cRNA des EAAT2 allein oder zusammen mit den jeweiligen Kinasen im Expressionssystem *Xenopus laevis* exprimiert und die [³H]-Glutamat Aufnahme als ein Maß für die EAAT2-Aktivität gemessen. Funktionelle Studien zeigten, dass die EAAT2-Aktivität durch Koexpression sowohl der SGK1 als auch ihrer Isoformen 2, 3 und PKB stimuliert wurde. Kürzlich konnte gezeigt werden, dass diese Kinasen auch potente Regulatoren des EAAT1 sind. Dieser stimulierende Effekt auf die EAAT1-Aktivität wird durch eine direkte Phosphorylierung des Transporters an der SGK-Phosphorylierungsstelle und einer Interaktion mit der Ubiquitinligase Nedd4-2 verursacht. Da EAAT2 keine SGK1-
Zusammenfassung

Konsensustelle enthält wurde untersucht, ob die Regulation des EAAT2 auf einer Interaktion mit der Ubiquitinligase Nedd4-2 beruht. In der Tat zeigte sich, dass der Transporter durch die Koexpression der Ligase Nedd4-2 inhibiert wird, ein Effekt der wiederum durch die Koexpression der SGK1 aufgehoben wird. Die Proteinkinase inhibiert die Ubiquitinligase Nedd4-2 durch ihre Phosphorylierung ohne, wie in Western Blots gezeigt, die Abundanz der Ligase zu verändern. Durch Chemilumineszenz konnte zudem gezeigt werden, dass die Stimulierung der EAAT2-Aktivität durch eine Erhöhung der Expresssion des Proteins an der Zelloberfläche verursacht wird. Die Erhöhung der EAAT2 Oberflächenexpression durch die Proteinkinase SGK ist möglicherweise ein neuer Mechanismus in der Regulation der neuronalen Erregbarkeit.

Der exzitatorische Aminosäuretransporter EAAT4 ist primär in den Purkinje Zellen und im cerebralen Cortex exprimiert. In diesen Zellen bewirkt der Transporter niedrige Konzentrationen des Glutamats unter toxischem Niveau. In einer vorherigen Studie konnte gezeigt werden, dass EAAT4 Abundanz und Funktion durch SGK1 und Nedd4-2 moduliert werden, aber der grundlegende Mechanismus konnte dabei nicht aufgeklärt werden. Expressionsstudien in Xenopus Oocyten zeigten, dass die [3H]-L-Glutamataufnahme und -oberflächenexpression durch die SGK1 gesteigert und durch die Ubiquitinligase Nedd4-2 vermindert werden. Ziel der vorliegenden Arbeit ist es, den molekularen Mechanismus der EAAT4-Modulation durch die Kinase zu erklären.

Im Gegensatz zum EAAT2 besitzt die Sequenz des EAAT4 zwei putative SGK1 Konsensus-Stellen am Amino- und Carboxy-Terminus (Thr40 und Thr504) die zwischen den verschiedenen Organismen stark konserviert sind. Um die potentielle Bedeutung dieser SGK Phosphorylierungsstellen in der EAAT4-Modulation durch die Proteinkinase aufzuklären wurden beide Stellen deletiert und das mutierte Protein allein oder zusammen mit der SGK1 exprimiert. Die Deletion beider SGK1 Phosphorylierungsstellen auf dem EAAT4-Protein (T40A, T504A) reduzierte den stimulierenden Effekt der Kinase auf die Funktion des Transporters und seine Oberflächenexpression. Von den beiden Phosphorylierungsstellen ist nur die erste (Thr40) für den stimulierenden Effekt verantwortlich da die T40A EAAT4 Aktivität und Abundanz nicht weiter durch die Proteinkinase moduliert wird. Die SGK1 hat möglicherweise, wie beim EAAT2 beschrieben, durch die Inhibition der
Zusammenfassung

Ubiquitinligase Nedd4-2 einen zusätzlichen Effekt auf EAAT4. Die Koexpression der SGK1 hebt den inhibierenden Effekt der Nedd4-2 auf und stimuliert dadurch die Expression des Transporters. Die Beteiligung der Ubiquitinligase Nedd4-2 an der Inhibition des EAAT4 konnte durch RNA-Interferenz nachgewiesen werden.

Die durch RNA-Interferenz vermittelte Inhibition der endogenen Nedd4-2 (xNedd4-2)-aktiviert die EAAT4-Funktion welche weiterhin durch die zusätzliche Expression der SGK1 stimuliert wird. In der Zusammenfassung moduliert die SGK1-Kinase die Aktivität des EAAT4 durch die Phosphorylierung des Transporters am Thr40 und auf indirektem Wege durch die Inhibition der Ubiquitinligase Nedd4-2. Deshalb spielt die SGK1 Proteinkinase möglicherweise eine wichtige Rolle bei der Homöostase der neuronalen Erregbarkeit im zentralen Nervensystem.
2 Summary

The Serum and Glucocorticoid inducible Kinase 1 (SGK1) is a protein kinase which regulates the function and expression of several ion channels and transporters. It was initially recognized as an immediate early gene whose mRNA level is increased in mammary tumour cell and fibroblast cell lines upon serum or glucocorticoids. The kinase is activated by phosphorylation in response to signals that stimulate phosphatidylinositol 3-kinase. The phosphorylation is mediated by 3-phosphoinositide-dependent protein kinase1 (PDK1) and PDK2/H-motif kinase. Once phosphorylated, the kinase regulates its targets activity through phosphorylation at the SGK1 consensus site (Arg-Xaa-Arg-Xaa-Xaa-Ser/Thr) or indirectly through inhibition of the ubiquitin ligase Nedd4-2. Nedd4-2 is an ubiquitin protein ligase that mediates binding of ubiquitin to its target proteins which tags them for degradation by the proteosome.

The sodium dependent excitatory amino acid transporter EAAT2 is a major glutamate carrier in the mammalian central nervous system. EAAT2 maintains the level of extracellular glutamate below the excitotoxic level. Defective expression of the transporter results in neuroexcitotoxicity that may contribute to neuronal disorders such as amyotrophic lateral sclerosis (ALS). SGK1 is expressed in the brain and interacts with the ubiquitin ligase Nedd4-2 to modulate membrane transporters and ion channels. The present study aimed to investigate whether SGK1 and its isoforms SGK2 and SGK3 as well as the related kinase, protein kinase B (PKB), regulate EAAT2.

To this end cRNA encoding EAAT2 alone or along with the kinases was expressed in Xenopus laevis oocytes and [3H] L-glutamate uptake was determined as a measure of EAAT2 activity. Functional studies demonstrated that EAAT2 activity is stimulated by coexpression of SGK1, its isoforms SGK2 and SGK3 as well as PKB. Regulation of the closely related glutamate transporter EAAT1 was recently shown to involve SGK1-3. The effect of these kinases on EAAT1 is mediated, in part, by direct phosphorylation of EAAT1 at the SGK1 consensus site on the transporter and by interference with the downregulating effect of the ubiquitin ligase Nedd4-2. Since EAAT2 does not contain any SGK consensus site, we
addressed whether the kinases modulate EAAT2 by impacting Nedd4-2 effects. In fact, the function of EAAT2 was diminished by Nedd4-2, an effect abrogated by additional coexpression of SGK1. The kinase inhibits Nedd4-2 through phosphorylation without altering Nedd4-2 protein abundance as demonstrated by western blotting of whole cell lysates. Chemiluminescence assays revealed that stimulation of EAAT2 activity is caused by the enhancement of the transporter abundance in the cell surface. Enhanced EAAT2 abundance by SGK1 might represent a novel mechanism in the regulation of neuronal excitability.

The excitatory amino acid transporter EAAT4 is predominantly expressed in Purkinje cells of cerebellar cortex. In those cells, EAAT4 keeps the level of extracellular glutamic acid in synaptic cleft below the toxic level. In a previous study EAAT4 abundance and function were shown to be modulated by SGK1 and Nedd4-2 but the precise mechanism of action remained undefined. Expression studies in *Xenopus* oocytes demonstrated that EAAT4-mediated $[^3]$H L-glutamate uptake and cell surface abundance are enhanced by coexpression of SGK1 and downregulated by coexpression of Nedd4-2. The present work aimed to identify the molecular mechanism of EAAT4 modulation by the kinase.

In contrast to EAAT2, EAAT4 sequence bears two putative SGK1 consensus sites at the amino and the carboxy terminus (Thr40 and Thr504) that are conserved among several species. To investigate the role of these putative SGK1 phosphorylation sites in EAAT4 modulation by SGK1, both sites were deleted and the mutated protein expressed alone or together with the kinase. Disruption of both SGK1 phosphorylation sites on EAAT4 ($T40A,T504A$EAAT4) reduced the kinase effect on transporter function and plasma membrane expression. From both phosphorylation sites, Thr40 appears to be responsible for the stimulatory effect since $T40A$EAAT4 activity and abundance was not further modulated by the kinase. SGK1 may additionally modulate transport through inhibition of the ubiquitin ligase Nedd4-2 as observed with the EAAT2 transporter. Coexpression of SGK1 inhibits the downregulating effect of Nedd4-2 on EAAT4 and thus stimulates the expression of the transporter. The significance of Nedd4-2 in the downregulation of EAAT4 was demonstrated by silencing intrinsic (*Xenopus*) Nedd4-2.
RNA interference-mediated silencing of endogenous Nedd4-2 (xNedd4-2) increased EAAT4 activity that was further stimulated upon additional SGK1 expression. In conclusion, the SGK1 kinase modulates EAAT4 activity through phosphorylation of the transporter at Thr40 and indirectly through inhibition of the ubiquitin ligase Nedd4-2. Hence SGK, through the regulation of EAAT2 and EAAT4 activity and expression might maintain proper neuronal excitability in the central nervous system.
3 Introduction

3.1 The Serum and Glucocorticoid inducible Kinase SGK1

The Serum and Glucocorticoid inducible protein Kinase 1 (SGK1) was identified in 1993 as an immediate early gene whose mRNA level increases noticeably within 30 minutes when mammary tumour or fibroblast cells are stimulated with serum or glucocorticoids\(^1\)\(^-\)\(^3\). SGK1 gene transcription was also shown to occur rapidly in response to many agonists like mineralocorticoids\(^4\)\(^-\)\(^6\), follicle stimulating hormone (FSH)\(^7\)\(^,\)\(^8\), transforming growth factor (TGF-\(\beta\))\(^9\)\(^,\)\(^10\), thrombin\(^11\), hypertonicity\(^12\)\(^-\)\(^14\), high glucose\(^9\)\(^,\)\(^11\) and neuronal injury or excitotoxicity\(^15\)\(^,\)\(^16\).

SGK1 is a member of the ‘AGC’ subfamily of serine/threonine protein kinases, which include protein kinase A (PKA) or adenosine 3’, 5’ monophosphate (cAMP)-dependent protein kinase, protein kinase G (PKG) or guanosine 3’, 5’ monophosphate (cGMP)-dependent protein kinase and isoforms of protein kinase C (PKC). SGK1 is present in the genomes of all eukaryotic organisms examined so far, including Caenorhabditis elegans, Drosophila, fish and mammals. Structure of SGK1 has been highly conserved through evolution like many other protein kinases\(^8\)\(^,\)\(^13\)\(^,\)\(^17\).

There are two other isoforms of SGK1 that have been identified in mammals and are named as SGK2 and SGK3. The catalytic domains of SGK2 and SGK3 isoforms share 80% amino acid sequence identity with one another and with SGK1\(^14\). The human gene encoding SGK1 was found in chromosome 6q23\(^17\). The gene encoding SGK2 was identified in chromosome 20q12 and SGK-like gene which encodes a protein having predicted amino acid sequence identical to that of human SGK3\(^18\) was found in chromosome 8q12.2.

SGK1 is expressed in all human tissues that have been studied including the pancreas, liver, heart, lung, skeletal muscle, placenta, kidney and brain\(^13\) but SGK1 is not expressed in all cell types within those tissues. For example, SGK1 transcript levels are found high in acinar cells in the pancreas\(^19\). High transcript levels of SGK1 are also found in the distal tubule and collecting duct of the kidney and in
thick ascending limb epithelial cells\textsuperscript{9}. The expression of SGK2 mRNA is restricted in human tissues. It express most abundantly in liver, kidney and pancreas\textsuperscript{20}. As like SGK1, SGK3 mRNA is present in all human and murine tissues examined but expression is particularly high in the mouse heart and spleen and in the embryo\textsuperscript{20,21}.

SGK1 has been observed as cytosolic in differentiated cells such as luteal cells\textsuperscript{22,23} or in tumour cells arrested in the G\textsubscript{1} phase of the cell division cycle by glucocorticoids\textsuperscript{24}. It has also been observed as nuclear in proliferating glomerulosa cells\textsuperscript{22,23} or mammary tumour cells during the S and G\textsubscript{2}-M phases of the cell cycle\textsuperscript{23}. However, the localization of SGK1 in any given cell is regulated by extracellular signals. Thus, in serum-stimulated mammary epithelial cells, the endogenously expressed SGK1 is nuclear, but becomes cytosolic after the inhibition of phosphatidylinositol (PI) 3-kinase. Translocation from the cytosol to the nucleus also occurs in response to serum stimulation of HEK293 or COS cells transfected with SGK1\textsuperscript{25}.

SGK1 is activated by phosphorylation through a signaling cascade including phosphatidylinositol (PI) 3-kinase and phosphoinositide dependent kinase PDK1 and PDK2/H-motif kinase. While PDK1 phosphorylates SGK1 at \textsuperscript{256}Thr, PDK2/H-motif kinase phosphorylates the kinase at \textsuperscript{422}Ser. SGK2 and SGK3 may similarly be activated by PDK1 and PDK2/H-motif kinase. The equivalent phosphorylation sites for SGK2 and SGK3 are found at \textsuperscript{193}Thr/\textsuperscript{356}Ser and \textsuperscript{253}Thr/\textsuperscript{419}Ser, respectively\textsuperscript{14,20,25}.

Replacement of the serine at position 422 by aspartate in the human SGK1 leads to the constitutively active S\textsubscript{422}D-SGK1 whereas replacement of lysine at position 127 with asparagine leads to the constitutively inactive K\textsubscript{127}N-SGK1. Analogous mutations in SGK2 and SGK3 lead to the constitutively active S\textsubscript{356}D-SGK2 and S\textsubscript{419}D-SGK3, and the constitutively inactive K\textsubscript{64}N-SGK2 and K\textsubscript{191}N-SGK3\textsuperscript{14}.

SGK isoforms resemble PKB in the substrate specificity, recognizing a serine or threonine residue lying in Arg-Xaa-Arg-Xaa-Xaa-Ser/Thr sequence (where Xaa is a variable amino acid) and thereby phosphorylating it\textsuperscript{14,20,25}.

SGK1 has a considerable physiological role through the regulation of transporters and ion channels. Sodium channel conductance stimulated by SGK1
Introduction

may result in cell volume regulation\textsuperscript{12,13,26}. SGK1 mediated activation of sodium channels leads to Na\textsuperscript{+} entry which in turn depolarizes the cell membrane. The depolarized cell membrane allows the entry of chloride ions and the accumulation of NaCl that further increases the intracellular osmolarity. The osmotic gradient makes water to enter the cell by which the volume of cell increases\textsuperscript{27,28}. SGK1 was found to stimulate Na\textsuperscript{+}, K\textsuperscript{+} and 2Cl\textsuperscript{−} cotransporter activity in the thick ascending limb of the kidney, a key nephron segment in urinary concentration, which is of importance in renal Na\textsuperscript{+} reabsorption\textsuperscript{9}. Abundant SGK1 gene transcription has been observed in diabetic nephropathy\textsuperscript{10,11,29}, fibrosing pancreatitis\textsuperscript{13} and inflammatory bowel disease\textsuperscript{19} but SGK1 involvement in the formation of abnormal fibrosis tissues remains to be established.

Moreover SGK1 and its isoforms are well proved in stimulating the activity and the cell membrane abundance of several transporters and ion channels. For instance, SGK isoforms regulate the epithelial Na\textsuperscript{+} channel, ENaC\textsuperscript{5}, the voltage-gated Na\textsuperscript{+} channel, SCN5A\textsuperscript{30}, the K\textsuperscript{+} channels ROMK1\textsuperscript{31}, KCNE1/KCNQ1\textsuperscript{32} and K\textsubscript{v}1.3\textsuperscript{33-35}, the Na\textsuperscript{+}/H\textsuperscript{+} exchanger NHE3\textsuperscript{36}, the dicarboxylate transporter NaDCT\textsuperscript{37}, the glutamate transporters EAAT1\textsuperscript{38}, EAAT3\textsuperscript{39}, EAAT4\textsuperscript{40} and EAAT5\textsuperscript{41} and the Na\textsuperscript{+}/K\textsuperscript{+}-ATPase\textsuperscript{42}. The regulatory activity of SGK1 plays a diverse role in essential cell functions such as epithelial transport, excitability, cell proliferation and apoptosis.

SGK1 might regulate epithelial Na\textsuperscript{+} transport via enhancing ENaC activity\textsuperscript{5,26,43} which has been proven to regulate transepithelial Na\textsuperscript{+} transport in kidney, lung and colon\textsuperscript{44}. The K\textsuperscript{+} channel KCNQ4 maintains electrical excitability in inner and outer hair cells of the inner ear and its activity is significantly stimulated by SGK1. KCNQ4's function is responsible for hearing ability and loss-of-funtion mutations in KCNQ4 gene leads to hearing loss\textsuperscript{45,46}. Hence SGK1 mediated stimulation of KCNQ4 activity might be necessary for excitability and it could contribute to the beneficial effect of glucocorticoids in hearing loss or vertigo\textsuperscript{47,48}. The role of SGK1 in the regulation of excitatory amino acid transporters (EAAT1, 3-5) is well established\textsuperscript{38,39,41}. The excitatory amino acid transporters maintain glutamate below toxic levels in the synaptic cleft of CNS and prevent severe neurological diseases such as amyotrophic lateral sclerosis\textsuperscript{49-52} and ischemia\textsuperscript{53-55}. 
The influence of SGK1 in regulation of K$^+$ channel further indicates its importance in cell proliferation$^{33-35}$. K$^+$ channels are considered to be important to maintain the cell membrane potential which is in turn required for proper function of the Ca$^{2+}$ release-activated Ca$^{2+}$ channel (I_{CRAC})$^{56}$. I_{CRAC} mediates Ca$^{2+}$ entry upon stimulation of cells with a wide variety of mitogenic factors, a prerequisite for triggering cell proliferation$^{57}$. SGK1 has been found involving in antiapoptotic pathway in part to phosphorylation of forkhead transcription factors, such as FKRHL1$^{21,58}$. SGK1 has also been shown to inhibit apoptosis of breast cancer cells$^{59}$.

To date, two modes of SGK1 action in regulating transporters and ion channels have been identified. It either regulates transporters by phosphorylating them at the putative consensus site (Arg-Xaa-Arg-Xaa-Xaa-Ser/Thr) or by inhibiting the downregulating effect of protein ubiquitin ligase Nedd4-2. These two modes of regulation of SGK1 were observed in epithelial Na$^+$ channel, ENaC$^{60,61}$ (Figure 1).
Figure 1 Schematic model showing molecular mechanisms of ENaC regulation by SGK1. Aldosterone binding to the mineralocorticoid receptor (MR) can stimulate the transcription of SGK1 as well as ENaC. Insulin or Insulin-like growth factor (IGF-1) phosphorylates SGK1 at Ser422 through PI3 kinase and PDK2/H-motify kinase signaling cascade. Activated (phosphorylated) SGK1 enhances ENaC plasma membrane abundance either directly by phosphorylating the channel or indirectly by inhibiting the downregulating effect of the ubiquitin ligase Nedd4-2.

3.2 The Protein Kinase B

The serine/threonine kinase Akt or protein kinase B (PKB) was discovered in 1991 in two independent lines of research. Bellacoasa’s group cloned the cellular homologue of the v-akt oncogene from a transforming retrovirus (AKT8) in spontaneous thymoma of the AKR mouse and named its product as c-AKT. Similarly Akt/PKB cDNA was cloned by Coffer’s group while searching for novel members of the protein kinase C (PKC) and by Jones’s groups while studying protein kinase A (PKA) superfamily as possible participants in signal transduction cascades. Jones’ group isolated a cDNA that encoded a protein kinase, termed RAC (related to the A and C kinases). The newly found kinase contains...
consensus sequences characteristic of a protein kinase catalytic domain and shows 73% and 68% similarity to PKC and PKA respectively. Three major isoforms of Akt/PKB namely, Akt1/PKBα, Akt2/PKBβ and Akt3/PKBγ encoded by three separate genes have been found in mammalian cells. These three isoforms have greater than 85% sequence identity and share the same protein structural organization. The first 100 amino acids of aminoterminal tail bear a pleckstrin homology (PH) domain that binds phospholipids. A short glycine-rich region that bridges the PH domain to the catalytic domain follows the PH domain. The last 70 amino acids of carboxy terminal tail contain a putative regulatory domain. All three Akt/PKB isoforms possess conserved threonine and serine residues (T308 and S473 in Akt1/PKBα).

Akt/PKB isoforms are ubiquitously expressed in mammals, although the levels of expression vary among tissues. Akt1/PKBα is the predominant isoform in most tissues including brain where it is markedly increased in regenerating neurons. Akt2/PKBβ expression is observed high in insulin-responsive-tissues comprising skeletal muscle, heart, liver and kidney. Akt2/PKBβ expression is further substantiated in developing embryos. In contrast to the first two isoforms, Akt3/PKBγ shows restricted pattern of expression. It expresses at high levels in testis and brain and low levels in the adult pancreas.

Akt/PKB isoforms can be rapidly activated by platelet derived growth factor (PDGF) studies in rodent fibroblasts showed that Akt/PKB is directly activated by PI3 kinase, which is activated by growth factor receptors through binding of its regulatory subunit to phosphotyrosine residues in the receptor. This is strongly suggested by the dependency of PKB on tyrosines Y740 and Y752 in the PDGF receptor that had been identified as the binding sites for the p85 regulatory subunit of PI3 kinase. PI3 kinase mediated PKB activation was also proved by the inactivation of PKB by the PI3 kinase inhibitors wortmannin and LY94002. Mechanism of Akt1/PKBα activation is recognized well and some studies demonstrate that same mechanism is true for both Akt2/PKBβ and Akt3/PKBγ according to different tissues and in response to different stimuli.
Akt/PKB possesses two phosphorylation sites, at carboxy-terminal tail (S473) and at activation loop of the kinase domain (T308), which are essential for the kinase activation by growth factors. Akt/PKB is activated by growth factors through the PI3 kinase signaling cascade. The growth factor which is recognized by tyrosine kinase receptors activates PI3 kinase which in turn catalyzes production of phosphoinositides phosphorylated at position 3 (PI(3,4,5)P3). PI(3,4,5)P3 binds to the PH domain of PDK1 and Akt/PKB and also activates PDK2/H-motif kinase. Activated PDK1 and PDK2/H-motif kinase phosphorylate Akt/PKB at S473 and T308 respectively and anchor the kinase to the plasma membrane (Figure 2).

**Activation of PKB by PI3 kinase**

![Diagram showing the activation of PKB by PI3 kinase](image)

**Figure 2 An outline of PKB activation by growth factor through PI3 kinase signalling cascade.**

The PI3 kinase mediated Akt/PKB activation suggests that Akt/PKB might be involved in growth factor mediated cell survival\textsuperscript{77-80} and might be capable of regulating basic metabolic functions such as protein and lipid synthesis, carbohydrate metabolism and transcription\textsuperscript{75}. The Akt/PKB isoform used in this study is Akt1/PKB\textalpha. Specifically T308D, S473D PKB mutant was employed and mimics the activated (phosphorylated) state by PDK1/2.
3.3 The Ubiquitin ligase Nedd4-2

The ubiquitination of proteins is an essential step in the degradation or processing of intracellular proteins in eukaryotic cells. This selective event takes place by conjugation of multiple ubiquitin molecules with target proteins. The ubiquitinated protein is in turn a target for a large 26S protease complex known as proteosome\textsuperscript{81,82} (Figure 3). The covalent attachment of ubiquitin, a highly conserved 76-amino acid polypeptide, to lysine residues of a substrate protein is required for proteosomal degradation\textsuperscript{81,83,84}.

Protein ubiquitination involves the cascade of three classes of enzymes: the ubiquitin-activating enzyme E1, the ubiquitin-conjugating enzyme (Ubc) or E2 and the ubiquitin-protein ligase E3\textsuperscript{81}. The E1 enzyme first activates an ubiquitin through the formation of a high-energy thiol ester bond between the carboxyl-terminal glycine of ubiquitin and the thiol group of a cysteine residue of E1. The ubiquitin is then transferred to a cysteine residue on one of the E2 members. The E2 enzymes may catalyse the attachment of the single ubiquitin to a substrate protein directly, or transfer the ubiquitin to E3 proteins. The E3 enzyme can catalyse the formation of an isopeptide bond between the carboxyl-terminal glycine of ubiquitin and the ε-amino group of lysine residues on a target protein. The attachment of additional ubiquitins by E3 enzyme eventually results in a multiply ubiquitinated substrate. The E3 is therefore believed to recognize specific substrate proteins that do not associate with E2 alone\textsuperscript{85}.
Human associated protein (E6AP) is an E3 enzyme that has been identified as functioning as an ubiquitin-protein ligase of tumour suppressor protein P53 in the presence of E6 onco-protein from human papilloma virus types 16 and 18. Putative E3 proteins contain a conserved region of approximately 350 amino acids homologous to the carboxyl-terminus of E6AP, termed ‘the homologous to E6AP carboxyl-terminus’ (HECT) domain. Nedd4 ubiquitin protein ligase is one of the HECT-E3 proteins and has been well studied in regulating ion channels and transporters including ENaC and EAAT1. Nedd4 ['NPC (Neuronal Precursor Cells)-Expressed, Developmentally Down-regulated 4'] gene was identified in 1992 as a developmentally regulated mouse gene highly expressed in early embryonic central nervous system. Nedd4 expression is not only restricted to the embryonic CNS, but is also expressed abundantly in tissues such as cortical collecting ducts in kidney and lung epithelia which are important tissues for Na+ channel function.

The Nedd4 has two isoforms namely Nedd4-1 (also named Nedd4, KIAA0093, or RPF1) and Nedd4-2 (also known as KIAA0439, LDI-1, Nedd4La, Nedd18, or Nedd4-L). The isoforms of Nedd4 has been studied intensively in the regulation of epithelial Na+ channel (ENaC). Nedd4-1 has one N-terminal calcium-dependent lipid binding domain (C2), a domain homologous to the E6-AP-COOH-terminal (HECT) and three to four WW domains with approximately 40
amino acids which are protein-protein interaction modules found in a variety of proteins\textsuperscript{98}. WW domains derive their name from the presence of two highly conserved tryptophan (W) residues and a conserved proline residue in the sequence of ~35 amino acids\textsuperscript{99}. These domains have a preference for binding small proline-rich sequences present in the target proteins called PY motifs, the most common of which is PPxY\textsuperscript{99} (P being proline and Y tyrosine residues). WW domains of some proteins can bind to alternative proline-rich motifs like PPLP\textsuperscript{100}, L being a leucine residue. The catalytic region of Nedd4, the HECT domain, contains a conserved cysteine residue that serves as an active site for the formation of thiol ester bond with an ubiquitin\textsuperscript{87,88,101}.

Nedd4-2 in the rat and mouse species has three WW domains, whereas in humans there are four WW domains which may be due to alternative splicing, as there is evidence for multiple transcripts in human Nedd4-1\textsuperscript{102}. Nedd4-2 has four WW domains and a HECT domain. Only \textit{Xenopus laevis} Nedd4-2 comprise a C2 domain, whereas such a domain appears to be lacking in mouse Nedd4-2\textsuperscript{98}. Figure 4 illustrates the structure of human and \textit{Xenopus} Nedd4-2.

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{structure.png}
\caption{Schematic illustration of human and \textit{Xenopus} Nedd4-2. Both human and \textit{Xenopus} Nedd4-2 contain four WW domains and a HECT catalytic domain. Only \textit{Xenopus} Nedd4-2 bears a C2 domain.}
\end{figure}

Nedd4-2 has several SGK1 phosphorylation sites which can be phosphorylated by SGK1 that leads to inactivation of the ubiquitin ligase (Figure 5).
By inactivating Nedd4-2, SGK1 can enhance the expression and activity of transporters (EAAT4)\(^6\) and ion channels (ENaC)\(^6\) indirectly.

**SGK1 consensus sites in Nedd4-2**

![Diagram of Nedd4-2](image)

<table>
<thead>
<tr>
<th>Species</th>
<th>Nedd4-2</th>
<th>Consensus Site 1</th>
<th>Consensus Site 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse</td>
<td>207...RLRSCS...212</td>
<td>323...RPRSLS...328</td>
<td></td>
</tr>
<tr>
<td>Human</td>
<td>377...RLRSCS...382</td>
<td>463...RPRSLS...468</td>
<td></td>
</tr>
<tr>
<td>Xenopus</td>
<td>333...RLRSCS...338</td>
<td>439...RPRSLS...444</td>
<td></td>
</tr>
<tr>
<td>Consensus</td>
<td>RXRXX(S/T)</td>
<td>RXRXX(S/T)</td>
<td></td>
</tr>
</tbody>
</table>

Figure 5 The xNedd4-2 sequence possesses two putative SGK1 phosphorylation sites at Ser338 and Ser444. Consensus sites of SGK1 in mouse and human Nedd4-2 are also indicated below.

Nedd4-2 mediated regulation is well studied in ENaC. The WW domains 3 and 4 of Nedd4-2 bind to the PY motif of ENaC and ubiquitinate the channel. Upon ubiquitination, ENaC is internalized and deubiquitinated. The deubiquitinated ENaC is either degraded by the lysosomes or relocated to the plasma membrane\(^9\). Figure 6 shows the ENaC downregulation by Nedd4-2.
3.4 Glutamatergic Neurotransmission

The amino acid L-glutamate is a major excitatory neurotransmitter in the mammalian central nervous system and is involved in most aspects of normal brain function including cognition, memory and learning\textsuperscript{103-105}. Glutamate also plays major roles in the development of the central nervous system, including synapse induction and elimination, and cell migration, differentiation and death\textsuperscript{106}. It has been implicated in many important physiological processes such as developmental plasticity, pathological conditions including epilepsy, cerebral ischemia, amyotrophic lateral sclerosis, Alzheimer’s disease, Parkinson’s disease and schizophrenia\textsuperscript{107}.

The glutamatergic neurotransmission begins with the release of glutamate from the synaptic vesicles to the synaptic cleft by exocytosis. The released glutamate activates three families of protein receptors\textsuperscript{107}. One family of glutamate receptors are NR1, NR2A, NR2B, NR2C and NR2D. They are collectively known as NMDA-receptors because they are activated by the glutamate analogue N-methyl-D-aspartate (NMDA). Second family of receptors is called AMPA and kainate receptors, which are activated by \(\alpha\)-amino-3-hydroxy-5-methyl-4-isoxazole
propionic acid (AMPA) and kainate respectively. AMPA-receptors are divided into subgroups namely GluR1-4 and kainate receptor’s subgroups are GluR5-9, KA1 and KA2. The NMDA and AMPA/kainate receptors are glutamate gated ion channels and are termed as ionotropic glutamate receptors. G-protein coupled receptors comprise the third family of glutamate receptors and are named as metabotropic receptors which are subdivided into groups I (mGluR1 and mGluR5), group II (mGluR2 and mGluR3) and group III (mGluR4, mGluR6, mGluR7 and mGluR8)\textsuperscript{107}. The glutamate neurotransmission is terminated by uptake of excessive glutamate from the synaptic cleft.

Glutamate uptake is accomplished by means of glutamate transporter proteins which use the electrochemical gradients across the plasma membrane as driving forces for uptake\textsuperscript{108}. Both neurons and glial cells express glutamate transporters (EAATs). Glutamate taken up by the cells may be used for metabolic purposes (protein synthesis, energy metabolism, ammonia fixation) or be reused as transmitter\textsuperscript{107}. Glutamate is transported into synaptic vesicles by a vesicular glutamate transporter (VGLUT) and subsequently released by exocytosis\textsuperscript{109-112}. In astrocytes, glutamate taken up from the extracellular fluid may be converted to glutamine which is released to the extracellular fluid, taken up by neurons and reconverted to glutamate inside neurons\textsuperscript{107} (Figure 7).
Glutamatergic neurotransmission

Figure 7 A schematic outline of glutamatergic neurotransmission. Upon an action potential glutamate (Glu) contained in vesicles in the presynaptic neurons is released to the synaptic cleft. Released glutamate activates glutamate (metabotropic and ionotropic-NMDA) receptors present on the post-synaptic neurons. To terminate transmission and in order to avoid excitotoxicity, glutamate is taken up by excitatory amino acid transporters (EAATs). Glutamate taken up by the cells may be stored in transmitter vesicles or be used for metabolic purposes. In neurons glutamate is transported into synaptic vesicles by a vesicular glutamate transporter (VGLUT). In astrocytes glutamate may be converted to glutamine (Gln). Released glutamine may be taken up by transporters (SN1) on neurons and converted to glucose.

The brain contains huge amounts of glutamate (about 5-15 mmol per kg wet weight depending on the region) and only a tiny fraction of this glutamate is normally present extracellularly\textsuperscript{113}. Glutamate uptake is a mechanism responsible for the maintenance of low extracellular concentrations of glutamate in the synaptic cleft. A defect in uptaking glutamate from the synaptic cleft results in the
accumulation of glutamate that causes neuroexcitotoxicity and neurodegeneration which is seen in epilepsy\textsuperscript{114-116}, ischemia\textsuperscript{53-55} and amyotrophic lateral sclerosis\textsuperscript{49-52}.

3.4.1 Excitatory Amino Acid Transporters (EAATs)

Excitatory amino acid transporters (EAATs) in the central nervous system (CNS) maintain extracellular glutamate concentration below excitotoxic levels and contribute to the clearance of glutamate released during neurotransmission\textsuperscript{106}. At least five structurally distinct subtypes of human glutamate transporters, EAAT1 – EAAT5 have been identified and characterized by molecular cloning.

In 1992, three groups simultaneously isolated cDNA clones of these transporters. Kanner’s group purified a transport protein from rat brain with biochemical methods\textsuperscript{117} and isolated a cDNA clone identified as GLT1 by using sequence information derived from a peptide fragment of this protein\textsuperscript{118}. Hediger’s group used expression cloning to isolate a clone called EAAC1 (Excitatory Amino Acid Carrier) from a cDNA library prepared from rabbit intestine\textsuperscript{119}.

Stoffel’s group while isolating a uridine diphosphate (UDP) galactose: ceramide galactosyltransferase from brain, always observed a co-chromatographing protein. After analysis of its sequence, they found a high homology to a bacterial $\text{H}^+$-dependent EAA transporter. A cDNA clone encoding a protein called GLAST (glutamate and aspartate transporter) was then isolated\textsuperscript{120}. Amara’s group isolated the human homologues of all three transporters and introduced the term EAAT1-3 for Excitatory Amino Acid Transporter\textsuperscript{121}. EAAT1 is homologue of GLAST, EAAT2 is homologue of GLT1 and EAAT3 is homologue of EAAC1. The sequence similarity of these transporters was used to obtain two other EAA transporter clones called EAAT4 and EAAT5\textsuperscript{122,123}.

EAATs have been isolated from a variety of eukaryotic species, including human (hEAAT1-5)\textsuperscript{121-124}, rat (GLAST-1, GLT-s, rEAAC1)\textsuperscript{118,120,125}, mouse (mEAAT1, mEAAT2, mEAAC1, mEAAT4)\textsuperscript{126-131}, rabbit (EAAC1)\textsuperscript{119}, Salamander (sEAAT1, -2A, -2B, -5A, -5B)\textsuperscript{132}, cow (bGLAST)\textsuperscript{133} and \textit{Drosophila melanogaster} (dEAAT)\textsuperscript{134}. In prokaryotes, gene encoding proton-dependent L-glutamate
transporters from *E.coli* (GltP), *Bacillus stearothermophilus* (GltT)\(^{135,136}\), and *Bacillus caldoltenax* (GltT) and dicarboxylic acid transporter (DctA) from *Rhizobium meliloti*\(^{137}\) are shown relatively high homology to the eukaryotic EAA carriers\(^{108}\).

EAATs are predominantly localized on presynaptic neurons and glial cells\(^ {106}\). EAAT1 and EAAT2 are distributed abundantly on astrocytic plasma membranes throughout the CNS\(^{138}\). Among the five subtypes EAAT2 is the most abundant glutamate transporter localized in the CNS. EAAT1 is the second abundantly present transporter\(^ {107}\). EAAT3 is found in highest concentrations in the hippocampus, cerebellum (Purkinje cells) and basal ganglia\(^{139,140}\). EAAT4 is selectively expressed on a GABAergic cell type, the cerebellar Purkinje cell and appears concentrated adjacent to excitatory synapse where glial cell membranes contact dendritic spines\(^{141-143}\). EAAT5 appears to serve a unique signalling function in photoreceptors of retina\(^{122,132,144}\). Three other EAATs are also been found in retina. They are EAAT1 in the Müller glial cells, EAAT2 in cone photoreceptors and cone bipolar cells, and EAAT3 in horizontal cells, amacrine cells and ganglion cells\(^{145,146}\).

Hydropathy analysis of excitatory amino acid transporters predicts six strongly hydrophobic transmembrane helices in the N-terminal half of the transporter and anywhere from 4-6 membrane-spanning regions in the C-terminal half\(^{108}\).

The conserved amino acid sequences of EAATs evidences to be highest in the C-terminal half of the transporter and in the putative transmembrane domains, whereas the least conserved regions are at the N and C termini\(^ {108}\). ‘AAXFIAQ’ motif in the C-terminal half of the transporter is noticeably conserved in both eukaryotic and prokaryotic members of this family and plays important role in transporter function\(^ {108}\). EAAT1-3 have two consensus sites for N-linked glycosylation (NXS/T) located in a large hydrophilic loop between 3\(^{rd}\) and 4\(^{th}\) transmembrane domains (TM)s. EAAT4 and EAAT5 have three and one N-linked glycosylation sites respectively\(^ {108}\).

Among the five glutamate transporters, only EAAT1 and EAAT4 have SGK1/PKB consensus sites on their sequence. EAAT1 has a consensus SGK1
phosphorylation site at Thr482 and EAAT4 has two putative SGK1 phosphorylation sites at Thr40 and Thr504. PKC is found to phosphorylate and internalize EAAT1\textsuperscript{147-150} and EAAT2\textsuperscript{149,151-153}. PKC mediated phosphorylation reduces the activity and cell surface expression of both EAAT1\textsuperscript{147-150} and EAAT2\textsuperscript{147,149,151-153}. A 43 amino acid domain in the C terminal of EAAT2 is necessary for PKC-dependent internalization\textsuperscript{149}. PKC activation increases EAAT3 mediated activity in C6 glioma cells and in \textit{Xenopus} oocytes\textsuperscript{154} and cell surface expression in neuron-enriched cultures\textsuperscript{149,155}, but controversially, Trotti \textit{et al} found that activation of PKC decreases EAAT3 mediated activity and cell surface expression in \textit{Xenopus} oocytes or in Madin-Darby Canine kidney cells\textsuperscript{156}. The precise mechanism of PKC mediated regulation of glutamate transporters is still elusive.

Transportation of glutamate by EAATs is an electrogenic phenomenon. The inward movement of glutamate across the membrane is thermodynamically coupled with the influx of two or three sodium ions and one proton and the efflux of one potassium ion\textsuperscript{157-159}. The cotransport of sodium ions provides the driving force for the concentrative uptake of glutamate which is necessary for maintaining low extracellular CNS concentration of glutamate\textsuperscript{108}. In addition, EAAT4 and EAAT5 possess ion channel like properties by adopting ligand-gated chloride conductance of substrate transport.

### 3.4.2 The Excitatory Amino Acid Transporter 2 (EAAT2)

The sodium coupled glutamate transporter EAAT2 is distributed abundantly on astrocytic plasma membranes associated with excitatory synaptic contacts\textsuperscript{160-162}. It is abundantly expressed in all brain regions, including the hippocampus, lateral septum, cerebral cortex and striatum.

EAAT2 is thermodynamically coupled to an inwardly directed sodium gradient. Glutamate influx is coupled to the cotransport of two to three sodium ions, one proton and the counter-transport of a potassium ion\textsuperscript{157-159}. The current generated by EAAT2 through Cl\textsuperscript{-} conductance is relatively small\textsuperscript{106,108,163}. It has two consensus N-linked glycosylation sites encoded in a large hydrophilic loop between 3\textsuperscript{rd} and 4\textsuperscript{th} transmembrane domains (TM)s\textsuperscript{108}.
Among the five subtypes of human EAATs, EAAT2 is the most abundant transporter in the CNS. Together with EAAT1, EAAT2 has the greatest impact on clearance of glutamate released during neurotransmission. As glutamate may exert neurotoxic effects, defective function or regulation of astroglial EAAT2 expression may foster neuroexcitotoxicity. Lack of EAAT2 has indeed been shown to promote extracellular glutamate accumulation, excitotoxicity and ultimately cell death. EAAT2 dysfunction has been reported in amyotrophic lateral sclerosis (ALS).

Despite the fundamental role of EAAT2 in CNS glutamate shuttling, only few studies have addressed the regulation of trafficking and function of this carrier. To date EAAT2 has been shown to be regulated by protein kinase C (PKC). PKC phosphorylates and internalizes EAAT2.

In the present study, coexpression experiments in *Xenopus laevis* oocytes have been used to examine the influence of SGK1, its isoforms SGK2 and SGK3 and the related protein kinase PKB on the glial glutamate transporter EAAT2.

### 3.4.2.1 The Excitatory Amino Acid Transporter 4 (EAAT4)

EAAT4 belongs to the family of sodium coupled glutamate transporters, which is predominantly expressed on a GABAergic cell type, the cerebellar Purkinje cells which are particularly sensitive to neuronal death and appears to be concentrated in dendritic areas that receive major glutamatergic inputs.

During ischemia, lack of EAAT4 correlates with loss of Purkinje cells supporting a role of EAAT4 in the protection of those cells. Efficient neuronal protection would require the adjustment of EAAT4 activity to the demand.

As like EAAT2, the transport of glutamate by EAAT4 is thermodynamically driven by an inwardly directed sodium gradient. Glutamate influx is coupled to the
cotransport of two to three sodium ions, one proton and the counter-transport of a potassium ion\textsuperscript{157-159}. EAAT4 also shows ligand gated chloride conductance as like EAAT5\textsuperscript{123,134,174}. The EAAT4 sequence bears three N-linked glycosylation sites and two putative SGK1 consensus sites (Thr40 and Thr504) at the amino and carboxy terminus that are conserved among several species.

The presence of the SGK1 consensus sites on the EAAT4 protein sequence suggests that the transporter might be directly phosphorylated by SGK1. In a previous study, EAAT4 activity and plasma membrane expression was shown to be upregulated by SGK1. The mechanism of SGK1 action remained however elusive. From ENaC regulation studies, SGK1 was found to stimulate the activity and the expression of ENaC by hindering the downregulating effect of the protein ubiquitin ligase Nedd4-2, but this mechanism of SGK1 action has not yet been demonstrated in the SGK1 mediated regulation of EAAT4.
4 Aim of the Study

The Serum and Glucocorticoid inducible protein Kinase 1 (SGK1) is well known to upregulate several ion channels and transporters such as the epithelial Na\(^+\) channel, ENaC, the renal chloride channel ClC-Ka/barttin, the K\(^+\) channel ROMK, the excitatory amino acid transporter EAAT4, and the sodium dependent glucose transporter SGLT1. The kinase exert its effects directly through phosphorylation of its targets or indirectly through inhibition of the ubiquitin ligase which otherwise tag its targets for internalization and degradation.

The major aim of this current work was to study the putative regulation of two sodium dependent glutamate transporters, EAAT2 and EAAT4, by SGK1 and Nedd4-2 in the *Xenopus laevis* oocyte expression system. Considering the key role of EAAT2 in regulating glutamate concentrations in the CNS, the elucidation of a regulatory mechanism of EAAT2 function and expression might have important implications in the regulation of neuroexcitability in health and disease.

This study aimed not only at investigating the significance of SGK1 in EAAT2 modulation but also of its isoforms SGK2 and SGK3 as well as PKB. Given that the closely related glutamate transporters EAAT1 is modulated by SGK1 in part through interference with the downregulating effect of the ubiquitin ligase Nedd4-2, the present work addressed whether the kinases modulate EAAT2 by impeding Nedd4-2 effects. The possibility that SGK1 and Nedd4-2 affect each others expression was also considered.

Recent studies demonstrated the ability of SGK1 to stimulate the activity and plasma membrane abundance of the excitatory amino acid transporter 4 (EAAT4). However the mechanism of SGK1 action remained elusive.

The present work was driven to identify the molecular mechanism of EAAT4 modulation by the kinase. The EAAT4 protein sequence bears two putative SGK1 phosphorylation sites which suggest SGK1 direct phosphorylation as the mechanism of EAAT4 modulation by the kinase. Here we investigated whether none, both or only a unique site is required for the SGK1 stimulatory effect. Nedd4-
2 has also been reported to modulate EAAT4 activity. Thus, SGK1 might enhance EAAT4 by inhibiting intrinsic *Xenopus* Nedd4-2. This mechanism of SGK1 action was also analysed.
5 Materials and Methods

5.1 Site Directed Mutagenesis

In order to quantify surface abundance of EAAT2 and EAAT4 on the oocytes membrane, an hemagglutinin tag (HA-tag) was introduced in an extracellular loop of transporters by two-stage PCR site-directed mutagenesis. The expression of HA-tagged transporters could be detected by a chemiluminescence assay by using an anti-HA antibody.

At the first stage of the two-stage PCR site-directed mutagenesis, two separate PCR reactions were performed, one with the forward primer and another with the reverse primer (Table 1) containing the HA sequence flanked by EAAT2 and EAAT4 specific sequences. In the second stage, the PCR products were mixed and further amplified as a single reaction. The first PCR consisted of 4 cycles of 30s at 94°C; 30s at 95°C; 1 min at 55°C; 2 min at 68°C and the second PCR consisted of 18 cycles of 30s at 94°C; 30s at 95°C; 1 min at 55°C; 2 min at 68°C. Table 2 indicates the composition of the PCR mixture as suggested by Stratagene (Heidelberg, Germany). Figure 8 shows a schematic outline of two-stage site-directed mutagenesis method.

<table>
<thead>
<tr>
<th>Protein</th>
<th>Forward Primer</th>
<th>Reverse Primer</th>
</tr>
</thead>
<tbody>
<tr>
<td>EAAT2-HA</td>
<td>5’GTCCAGCCTGGATTAC GACGTACCAGATTACGC TGCCTTCCT GGACC 3’</td>
<td>5’GGTCCAGGGAAGGCA GCGTAATCTGGTACGT CGTAATCCAGGCTGGA C 3’</td>
</tr>
<tr>
<td>EAAT4-HA</td>
<td>5’GGGTCAGAGTTGGGG TACGACGTACCAGATTAC GCTGCCTCCATTTCGCC 3’</td>
<td>5’GGAGAAATGGAGG CAGCGTAATCTGGTAC GTCGTACCCCAACTCT GACC 3’</td>
</tr>
</tbody>
</table>

Table 1 Forward and reverse primers used to generate EAAT2-HA and EAAT4-HA.
### Materials and Methods

<table>
<thead>
<tr>
<th>PCR reaction mixture</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>10X Pfu buffer</td>
<td>5 µl</td>
</tr>
<tr>
<td>10 mM primer</td>
<td>1 µl</td>
</tr>
<tr>
<td>Plasmid template</td>
<td>0.1 – 0.2 µg</td>
</tr>
<tr>
<td>10 mM dNTP mix</td>
<td>1 µl</td>
</tr>
<tr>
<td>H\textsubscript{2}O</td>
<td>Final volume of 50 µl</td>
</tr>
<tr>
<td>\textit{Pfu} turbo polymerase</td>
<td>1 µl</td>
</tr>
</tbody>
</table>

**Table 2 PCR reaction mixture for two-stage PCR site-directed mutagenesis.**

![Diagram](image)

**Two-stage PCR site-directed mutagenesis**

- Forward and reverse primer containing HA sequence are used to introduce HA tag into EAAT2/4 gene in two separate PCR reactions.
- Template DNAs with inserted HA gene from previous step are mixed together and further amplified by PCR.
- Amplified template DNA contains the HA sequence in EAAT2/4 gene.

**Figure 8 Main steps of two-stage PCR site-directed mutagenesis.**

The final PCR product contains a mixture of wildtype and mutated plasmid DNA. In order to get rid of the wildtype DNA, the PCR product was digested with 1 µl of \textit{Dpn} I enzyme (10U/µl) which only digests methylated parent (template) DNA. The \textit{Dpn} I digested PCR product was then transformed into \textit{E.coli} XL1-Blue Supercompetent cells by a heat shock method and plated onto LB plates. Grown
bacteria were picked and inoculated into LB media for further DNA isolation and RNA synthesis. Mutants were sequenced to verify the presence of the desired mutation.

The site-directed mutagenesis technique was also performed to eliminate putative SGK1 phosphorylation sites on EAAT4. The phosphorylation sites at Thr40 and Thr504 position on EAAT4 were eliminated separately to generate $^{T40A}$EAAT4, $^{T504A}$EAAT4 single mutants according to the manufacturer’s (QuikChange site-directed mutagenesis kit, Stratagene, Heidelberg, Germany) instructions. By using $^{T40A}$EAAT4 as a template, phosphorylation site at Thr504 position on EAAT4 was eliminated to generate the double mutant $^{T40AT504A}$EAAT4 which lacks both SGK1 phosphorylation sites. These mutants were used to study the stimulation of EAAT4 activity and plasma membrane abundance by SGK1 in the absence of one or both phosphorylation sites. The primers used to generate these mutants are listed in Table 3 below. All other mutants used in this work were prepared by other collaborators. Table 4 indicates the composition of the PCR mixture as suggested by Stratagene (Heidelberg, Germany).
### Materials and Methods

<table>
<thead>
<tr>
<th>Protein</th>
<th>Forward Primer</th>
<th>Reverse Primer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>T40A EAAT4</strong></td>
<td>5´ CGCTTGCGCCTGCAG GCCATGACCCCGAGAGC 3´</td>
<td>5´ CCCCAAGTACA TTGGCCATCGTAC GAAGTCG 3´</td>
</tr>
<tr>
<td><strong>T504A EAAT4</strong></td>
<td>5´ GCTCTCGGGGTATGG CCTGCAGGCGCAAGCG 3´</td>
<td>5´ CCCCAAGTACAT TGGCCATCGTACG AAGTCG 3´</td>
</tr>
<tr>
<td><strong>S356D SGK2</strong></td>
<td>5´ GCATTCCTGGGATTTG ATTATGCGCCAG AGG 3´</td>
<td>5´ CCTCTGGCGCAT AATCAAATCCAGG AATGC 3´</td>
</tr>
<tr>
<td><strong>S419D SGK3</strong></td>
<td>5´ GATGCATTCGGGATTTG TCGATTATGCACCTCCTT CAG 3´</td>
<td>5´ CTGAAGGAGGTTG CATAATCGAAACCA ACGAAATGCATC 3´</td>
</tr>
</tbody>
</table>

Table 3 Forward and reverse primers used to generate **T40A EAAT4**, **T504A EAAT4**, **S356D SGK2** and **S419D SGK3**.

<table>
<thead>
<tr>
<th>PCR reaction mixture</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 X reaction buffer</td>
<td>5 µl</td>
</tr>
<tr>
<td>dsDNA template</td>
<td>5-50 ng</td>
</tr>
<tr>
<td>Oligonucleotide primer 1</td>
<td>125 ng</td>
</tr>
<tr>
<td>Oligonucleotide primer 2</td>
<td>125 ng</td>
</tr>
<tr>
<td>dNTP mix</td>
<td>1 µl</td>
</tr>
<tr>
<td>Pfu Turbo DNA polymerase (2.5 U/µl)</td>
<td>1 µl</td>
</tr>
</tbody>
</table>

Table 4 PCR reaction mixture used to generate **T40A EAAT4**, **T504A EAAT4** and **T40A504A EAAT4 mutants**.
5.1.1 Transformation of E.coli XL1-Blue Supercompetent Cells

_E.coli_ XL1-Blue Supercompetent cells from Stratagene, (Heidelberg, Germany) were thawed on ice and 50 µl of the supercompetents cells were taken into a prechilled Falcon 2059 polypropylene tube. 1 µl of _Dpn_ I-treated DNA sample was added to the aliquots of supercompetent cells. The tube was gently vortexed to mix the content and incubated on ice for 30 minutes. Transformation reaction was started by keeping the tube at 42°C for 45 seconds which make bacteria to open their pores on the cell wall to provide entry of DNA and then suddenly placed on ice for 2 minutes which allows bacteria to close the cell wall pores.

0.5 ml of preheated (42°C) NZY broth was added to the heat-shock treated supercompetent cells and incubated at 37°C for 1 hour with shaking at 220 rpm. Then 250 µl of DNA transformed bacterial cells were plated on agar plates. LB plates were incubated at 37°C overnight.

From LB plates several clones were picked and bacteria were grown in LB broth to get more quantity of bacterial cells to isolate transformed plasmids for further experiments. The mutant plasmids from _E.coli_ cells were isolated and purified with Qiagen (Hilden, Germany) DNA plasmid midi purification kit according to the manufacturer’s instructions. The purified plasmids were sequenced to confirm the desired mutation.

5.2 Preparation of cRNA

To study the function and expression of transporters, cRNAs of transporters were injected into _Xenopus laevis_ oocytes. The mutant DNAs including EAAT2-HA, T40A EAAT4, T504A EAAT4 and T40AT504A EAAT4, were used as a template to synthesize cRNA. cRNAs of SGK and PKB kinases and Nedd4-2 were also synthesised by the same method. RNA synthesis protocol possesses two steps: linearization of the plasmid DNA containing the sequence of interest and generation of cRNA itself.
5.2.1 Plasmid DNA linearization

The restriction endonuclease was used to make a cut at the 3’ end of the insert and to yield a 5’ blunt end. Specific restriction enzymes used to linearize each plasmid used in this study are shown in Table 5.

<table>
<thead>
<tr>
<th>Protein</th>
<th>Plasmid</th>
<th>Restriction Endonuclease</th>
</tr>
</thead>
<tbody>
<tr>
<td>S422D SGK1</td>
<td>pGHJ</td>
<td>Not I</td>
</tr>
<tr>
<td>SGK2 and SGK3</td>
<td>pGHJ</td>
<td>Not I</td>
</tr>
<tr>
<td>PKB</td>
<td>pGHJ</td>
<td>Sal I</td>
</tr>
<tr>
<td>human Nedd4-2, and S382D,S468D Nedd4-2</td>
<td>pGHJ</td>
<td>Hind III</td>
</tr>
<tr>
<td>C962S Nedd4-2</td>
<td>pGHJ</td>
<td>Bgl II</td>
</tr>
<tr>
<td>human EAAT2-HA</td>
<td>pOTV</td>
<td>Spe I</td>
</tr>
<tr>
<td>rat EAAT4, EAAT4-HA, T40A EAAT4, T504A EAAT4 and T40AT504A EAAT4</td>
<td>pGHJ</td>
<td>Xba I</td>
</tr>
<tr>
<td>GLUT1</td>
<td>pSP64T</td>
<td>Xba I</td>
</tr>
</tbody>
</table>

Table 5 Plasmids containing desired gene encoding for specific proteins and restriction endonuclease enzymes used to linearize each plasmid.

The reaction mixture as mentioned in the table below was prepared and incubated at 37°C for 2 hours. Then DNA was precipitated with 1 volume of isopropanol (50 µl) and 1/10 volume of 3 M sodium acetate, pH 5.2 (5 µl) and incubated at room temperature for 10 minutes. Reaction mixture was centrifuged at 17000 rpm for 15 minutes at 4°C. After removing the supernatant, the pellet was washed twice with 70 % ethanol (100 µl) at 17000 rpm for 10 minutes. Ethanol was removed from the last wash and the pellet was dried using the Eppendorf Concentrator (Eppendorf, Hamburg, Germany) at 35-45°C for 5 minutes.
5.2.2 cRNA synthesis

The linearized DNA produced from the above mentioned method was used as a template to generate cRNA. The reaction mixture given in table 7 was taken in a sterile eppendorf tube.

<table>
<thead>
<tr>
<th>Reaction mixture</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Linearised DNA (1 µg)</td>
<td>10 µl</td>
</tr>
<tr>
<td>10 X Buffer</td>
<td>2.5 µl</td>
</tr>
<tr>
<td>rNTPs</td>
<td>1 µl</td>
</tr>
<tr>
<td>Cap analogue</td>
<td>2.5 µl</td>
</tr>
<tr>
<td>RNase inhibitor</td>
<td>1 µl</td>
</tr>
<tr>
<td>Water</td>
<td>8 µl</td>
</tr>
</tbody>
</table>

Table 7 Reaction mixture used to synthesis RNA from the linearized DNA.

The reaction mixture was gently spanned and appropriate RNA polymerase (Table 8) was added and pulse spanned again. The reaction mixture was incubated at 37°C when using T3 or T7 polymerases or at 40°C when using SP6 polymerase for 1 hour. Then 1 µl of Dnase was added to remove the possible DNA contamination in the reaction mixture. Finally reaction mixture was incubated at 37°C for 15 min by shaking.
Table 7 RNA polymerases used to prepare cRNA and amount of cRNA injected into oocytes.

<table>
<thead>
<tr>
<th>Protein</th>
<th>RNA Polymerase</th>
<th>cRNA (ng/oocyte)</th>
</tr>
</thead>
<tbody>
<tr>
<td>S422D SGK1, S386D SGK2 and S419D SGK3</td>
<td>T7</td>
<td>7.5</td>
</tr>
<tr>
<td>PKB</td>
<td>T7</td>
<td>7.5</td>
</tr>
<tr>
<td>human Nedd4-2, C962S Nedd4-2 and S382D.S468D Nedd4-2</td>
<td>Sp6</td>
<td>12.5</td>
</tr>
<tr>
<td>human EAAT2-HA</td>
<td>T7</td>
<td>10</td>
</tr>
<tr>
<td>rat EAAT4, EAAT4-HA, T40A EAAT4, T504A EAAT4 and T40AT504A EAAT4</td>
<td>T7</td>
<td>10</td>
</tr>
<tr>
<td>Glut1</td>
<td>Sp6</td>
<td>1</td>
</tr>
</tbody>
</table>

To purify the generated RNA, 100 µl DEPC water and 125 µl of phenol-chloroform mixture was added and centrifuged at maximum speed for 2 minutes. The upper inorganic phase was carefully taken into a new Eppendorf tube and 12.5 µl of 3 M sodium acetate (pH 5.2) and 375 µl of 100% ethanol was added and mixed by pulse vortex and further incubated at -70 °C overnight.

After incubation, the mixture was centrifuged at 17000 rpm for 15 minutes at 4 °C. The supernatant was removed and the pellet was washed twice with 200 µl of 70% ethanol. Finally the pellet was dried at room temperature and reconstituted in 25 µl of DEPC water and vortexed. Then concentration of RNA was measured by taking 1 µl of RNA in 69 µl water using an Eppendorf Biophotometer (Hamburg, Germany). The quality of the RNA generated was checked by gel electrophoresis.

5.3 Xenopus laevis oocyte preparation

*Xenopus laevis* oocytes were used as an expression system to study function and plasma membrane abundance of transporters. Prior to isolation of oocytes, female *Xenopus laevis* frogs were anaesthetized by submersion in a 0.1%
Materials and Methods

3-aminobenzoic acid ethyl ester solution (Sigma, St. Louis, Mo, USA) for 15-20min and placed on ice for surgery. Through a small abdominal incision (1-2 cm in length) small pieces of ovary were removed carefully without injuring any blood capillaries and the wound was subsequently closed with a reabsorbable suture. Frogs were kept wet but not under water until reflexes were fully recovered to prevent drowning.

The ovarian sacs were manually tore apart and oocytes were separated with fine tweezers in OR2 solution (82.5 mM NaCl, 2 mM KCl, 1mM MgCl$_2$ and 5 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), pH 7.5). Enzymatic defolliculation was achieved by treatment of ovarian lobes with OR2 solution with 1 mg/ml collagenase (Biochrom, Berlin, Germany) for about 60-120 min at room temperature. The flask was slightly shaken to ensure even digestion.

To stop defolliculation, oocytes were repeatedly washed with ND96 (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl$_2$, 1 mM MgCl$_2$, and 5 mM HEPES, pH 7.65) to remove all detritus and collagenase. Large oocytes (stage V-VI) showing evenly coloured poles and a sharp border between both poles were selected and stored overnight in a ND96 storage solution (complemented after sterilisation with 5 mM pyruvate, 50 µg/ml gentamycin and 0.5 mM theophylline) at 15 °C. Gentamycin helps preventing infections and theophylline inhibits the further maturation of the oocytes. Figure 9 depicts oocyte preparation and cRNA injection.
Materials and Methods

Oocytes preparation and injection

Frog was operated and oocytes were separated from ovarian sacs, then treated with collagenase.

After collagenase treatment oocytes were washed, sorted (stage V and VI) and incubated in ND 96 at 15°C.

Sorted oocytes were injected with cRNA and again incubated in ND 96 at 15°C.

Figure 9 An overall view of oocytes preparation, cRNA injection and protein expression in oocytes.

5.4 Protein expression in Xenopus laevis oocytes

Oocytes were injected with kinases $^{S422D}_{SGK1}$, $^{S356D}_{SGK2}$, $^{S419D}_{SGK3}$ and $^{T308D, S473D}_{PKB}$ cRNA and/or wild type or mutated Nedd4-2 cRNA or H$_2$O on the first day after preparation of the oocytes and subsequently with EAAT2-HA, EAAT4 or its mutant cRNAs next day. For RNAi, experiments 1.5 ng of double-stranded siRNA 19-mer oligo (Invitrogen Corporation, Carlsbad, California, USA) corresponding to bases 2707-2725 of xNedd4-2 was injected into oocytes on the first day and then next day oocytes were injected with $^{S422D}_{SGK1}$ and EAAT4-HA in two hours interval.
Materials and Methods

On the fifth day of kinase injection tracer uptake measurement was carried out to study the activity of the transporters. On the same day chemiluminescence assay was performed to study the plasma membrane abundance of the transporters. Oocytes were lysed and proteins isolated to perform western blotting to address proper protein expression and assessment of RNAi gene silencing at the protein level.

5.5 Nedd4-2 RNA Silencing by siRNA

The indirect mechanism of EAAT4 stimulation by SGK1 through inhibiting the downregulating effect of Nedd4-2 could be analysed by silencing Nedd4-2 of Xenopus oocytes. The small interfering RNA (siRNA) technique was employed to silence the intrinsic Nedd4-2. Using Ambion® siRNA Target Finder, siRNA for Nedd4-2 was designed online. Chosen siRNA corresponds to bases 2707-2725 of xNedd4-2 within is the catalytically active region. Chemically synthesized Nedd4-2 siRNA was bought from Invitrogen Corporation (Carlsbad, California, USA). Figure 10 depicts siRNA mode of action. The silencing activity of siRNA starts with the introduction of a long piece of double stranded RNA (dsRNA) into the eukaryotic cell. In the natural pathway, the dsRNA is sliced into smaller pieces by an enzyme named ‘dicer’. The small pieces of RNA are called small interference RNA (siRNA) which complex with a number of proteins and form RNA-induced silencing complex (RISC). RISC unwinds siRNA into single strand and thereby RISC-siRNA complex targets mRNA. The targeted mRNA hybridizes with and is degraded by the siRNA.
Materials and Methods

1.5 ng of double-stranded siRNA 19-mer oligo was injected into oocytes on the first day after oocytes´ preparation and EAAT4 and/or SGK1 was injected on the following day. On the fifth day of the injection tracer flux measurement was done to observe the activity of the transporter coexpressed with siRNA and/or with SGK1. For the assessment of RNAi gene silencing at the protein level, oocytes were lysed on the same day that functional experiments were performed and western blotting was carried out as described below.

5.6 Tracer Flux Measurements

Function of the transporters was demonstrated by means of tracer flux measurements. The transport assay was performed on the fifth day after cRNA
Materials and Methods

injection. 5-10 single oocytes were incubated in 500 µl of ND96-Na (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl₂, 1 mM MgCl₂ and 5 mM HEPES, pH 7.65) containing 1 µCi [³H] L-glutamate and 10 µM of unlabelled L-glutamate and another set with the same number of oocytes were incubated in ND96-Ch (96 mM ChCl, 2 mM KCl, 1.8 mM CaCl₂, 1 mM MgCl₂ and 5 mM HEPES, pH 7.65) where NaCl was substituted by choline chloride (ChCl).

After incubation for 10 minutes with L-glutamate (linear range of uptake), uptake was terminated by washing the oocytes four times with 3 ml of ice-cold ND96-Na and ND96-Ch containing 1 mM unlabelled L-glutamate. Oocytes were individually transferred into scintillation vials and dissolved by adding 200 µl of 10% SDS before the radioactivity was determined. Uptake values obtained with ND96-Ch were always subtracted from the values obtained with ND96-Na, because EAAT2 and EAAT4 are sodium dependent glutamate transporters which uptake glutamate with influx of two to three sodium ions and one proton with efflux of one potassium ion.

For determination of GLUT1 activity, tritium-labeled 2-deoxy-D-glucose ([³H] 2-DOG) was used as the glucose analogue. The GLUT1 transport assay was performed 4 days after cRNA injection and contained 5-10 single oocytes in 0.25 ml of ND96 (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl₂, 1 mM MgCl₂ and 5 mM HEPES, pH 7.4) containing 1 µCi of [³H] 2-DOG and 50 µM of unlabelled 2-DOG. After incubation for 30 min at room temperature with 2-DOG (linear range of uptake), uptake was terminated by washing the oocytes four times with 3 ml of ice-cold ND96. Oocytes were individually transferred into scintillation vials and dissolved by adding 200 µl of 10% SDS before the radioactivity was determined.

5.7 Detection of Cell Surface Expression by Chemiluminescence

To quantify abundance of the transporters expressed on the plasma membrane of oocytes, chemiluminescence assay was employed. On the fifth day of kinase injection oocytes were incubated in 400 µl of ND96 with 1% BSA solution for 20 min at room temperature as a blocking step. Oocytes were then incubated with 1
µg/ml primary rat monoclonal anti-HA antibody (clone 3F10, Boehringer, Germany), which can detect the haemagglutin tag inserted into the extracellular loops of EAAT2 and EAAT4 in 200µl of ND96 with 1%BSA solution.

After an hour of incubation at room temperature, oocytes were washed with 400 µl of ND96 with 1% BSA for 5 times in 30 minutes. 2 µg/ml secondary, peroxidase-conjugated affinity-purified F(ab')2 goat anti-rat IgG antibody (Jackson ImmunoResearch, West Grove, USA) was added to oocytes in 200 µl of ND96 with 1% BSA and incubated for 1 hour. Oocytes were again washed with 400 µl of ND96 with 1% BSA for 10 times in one hour. Finally oocytes were washed with 400 µl of ND96 alone for 3 times in 15 min.

Individual oocytes were placed in 96 well plates with 100 µl of ND96 and 20 µl of SuperSignal ELISA Femto Maximum Sensitivity Substrate (Pierce, Rockford, USA), was added to each well. Chemiluminescence was quantified in a luminometer (Wallac Victor 2 plate reader, Perkin Elmer, Juegesheim, Germany) by integrating the signal over a period of 1 second. Results are given in relative light units (RLU).

RLU obtained with H₂O-injected oocytes (control oocytes) were subtracted from the values obtained with oocytes injected with EAAT2-HA and EAAT4-HA alone or together with the respective SGK isoforms and/or Nedd4-2. In the relevant range of protein expression, the chemiluminescence amplitude correlates linearly with the protein abundance at the cell membrane\(^{175}\). Figure 11 shows an overview of the performed cell surface assay.
Materials and Methods

5.8 Western Blotting

The expression of SGK1, Nedd4-2 and GAPDH was analyzed by western blotting. Briefly, oocytes were homogenized in lysis buffer containing 50 mM Tris (pH 7.5), 0.5 mM EDTA (pH 8.0), 0.5 mM EGTA, 100 mM NaCl, 1 % Triton X-100, 100 µM sodium orthovanadate and protease inhibitor cocktail (Roche, Mannheim, Germany) at the recommended concentration.

Proteins were separated on an 8 % polyacrylamide gel and transferred to nitrocellulose membranes. After blocking with 5 % non-fat dry milk in PBS / 0.15 % Tween 20 for 1h at room temperature, blots were incubated overnight at 4°C with a rabbit Nedd4-2 antibody (diluted 1:1000 in PBS / 0.15 % Tween 20 / 5 % non-fat dry milk), a rabbit anti-SGK1 antibody (Upstate, Waltham, MA, USA, diluted 1:1000 in PBS / 0.15 % Tween 20 / 5 % non-fat dry milk) or a rabbit anti-GAPDH HRP conjugated antibody (Santa Cruz Biotechnology, Heidelberg, Germany, diluted 1:1000 in PBS / 0.15 % Tween 20 / 5 % non-fat dry milk). GAPDH was used to demonstrate equal amount of protein loading. Secondary peroxidase-conjugated
sheep anti-rabbit IgG (diluted 1:1000 in PBS / 0.15 % Tween 20 / 5 % non-fat dry milk) were used for chemiluminescent detection with enhanced chemiluminescent ECL kit (Amersham, Freiburg, Germany). Band intensities were quantified using Quantity One® Analysis software (Biorad, Munich, Germany).

\section*{5.9 Statistical Analysis}

Data are provided as means ± SEM, n represents the number of oocytes investigated. All experiments were repeated with at least 3 batches of oocytes; in all repetitions qualitatively similar data were obtained. All data were tested for significance using ANOVA, and only results with $P < 0.05$ were considered as statistically significant.
6 Results

6.1 Modulation of EAAT2 by SGK1-3 and PKB

6.1.1 SGK1 stimulates EAAT2 activity and plasma membrane abundance

To evaluate the role of SGK1 in EAAT2 regulation, the transporter was expressed in *Xenopus laevis* oocytes in the absence and presence of the kinase and \[^{3}H\] L-glutamate uptake was determined as a measure of EAAT2 activity. \(^{S422D}\)SGK1-mediated glutamate uptake increased upon coexpression of SGK1 (from 1.94 ± 0.38 pmol/10 min/oocyte in EAAT2-HA expressing oocytes to 3.52 ± 0.32 pmol/10 min/oocyte in oocytes coexpressing EAAT2-HA with \(^{S422D}\)SGK1, \(n = 22\)) (Figure 12). Increased EAAT2 activity could be caused by enhanced expression of the transporter in the plasma membrane. To determine EAAT2 plasma membrane abundance we performed chemiluminescence assays by using an anti-HA antibody that recognizes an HA tag placed in an extracellular loop within the EAAT2 sequence (EAAT2-HA). Data obtained demonstrate that \(^{S422D}\)SGK1 stimulates EAAT2 plasma membrane expression up to two fold (\(n = 35-37\), Figure 13).

![Figure 12](image)

**Figure 12** \(^{S422D}\)SGK1 stimulates the activity of EAAT2-HA when coexpressed in *Xenopus laevis* oocytes. Arithmetic means ± SEM. * indicates statistically significant difference to uptake in *Xenopus* oocytes expressing EAAT2-HA alone. \(n = 21-23\).
Figure 13 SGK1 stimulates the plasma membrane abundance of EAAT2-HA when coexpressed in *Xenopus laevis*. Arithmetic means ± SEM. * indicates statistically significant difference to the EAAT2 abundance in *Xenopus* oocytes expressing EAAT2-HA alone. n= 35 - 37.

6.1.2 SGK1 isoforms SGK2-3 and PKB similarly stimulate Nedd4-2 plasma membrane abundance

To explore whether the SGK1 isoforms (SGK2-3) and PKB are also able to increase glutamate transport mediated by EAAT2, the different constitutively active SGK kinase isoforms were coexpressed with the transporter and labelled glutamate uptake was measured. Figure 14 shows that $^{S356D}$SGK2 and $^{S419D}$SGK3 upregulate EAAT2 as well (from 1.94 ± 0.38 pmol/10 min/oocyte in EAAT2-HA expressing oocytes to 4.72 ± 0.54 pmol/10 min/oocyte and 5.99 ± 0.87 pmol/10 min/oocyte in oocytes coexpressing EAAT2-HA with $^{S356D}$SGK2 and $^{S419D}$SGK3 respectively, n= 23). We also quantified cell surface expression of the carrier in the presence of
Results

S356D°SGK2 and S419D°SGK3. As demonstrated in Figure 15, carrier abundance in the oocyte membrane was similarly upregulated up to 2.3 fold by S356D°SGK2, S419D°SGK3 and T308D, S473D°PKB (n= 35-37).

Figure 14 S356D°SGK2 and S419D°SGK3 enhance the activity of EAAT2-HA when coexpressed in Xenopus laevis oocytes. Arithmetic means ± SEM. * indicates statistically significant difference to uptake in Xenopus oocytes expressing EAAT2-HA alone. n= 23.
Figure 15  $^{S356D}$SGK2 and $^{S419D}$SGK3 increase the plasma membrane abundance of EAAT2-HA when coexpressed in *Xenopus laevis* oocytes. * indicates statistically significant difference to the EAAT2 surface abundance in *Xenopus* oocytes expressing EAAT2-HA alone. n= 35-37.

6.1.3 SGK1 enhances EAAT2 by inhibiting Nedd4-2 effects without altering Nedd4-2 expression

EAAT2 does not bear any putative SGK1 phosphorylation site on its sequence, thus the transporter cannot be directly enhanced by the kinase. In order to test whether SGK1 is effective through inhibition of the ubiquitin ligase Nedd4-2, we analyzed the impact of several Nedd4-2 mutants on EAAT2 activity. We used a catalytically inactive $^{C962S}$Nedd4-2 and a Nedd4-2 mutant that mimics the phosphorylation state of Nedd4-2 when expressed with SGK1 ($^{S382D, S468D}$Nedd4-2). Both sites (S382D, S468D) have been shown to be phosphorylated by SGK1 and in
the context of ENaC regulation by Nedd4-2, phosphorylation at these sites prevents Nedd4-2 binding to ENaC\textsuperscript{60}. We therefore evaluated whether C\textsuperscript{962S}Nedd4-2 and S\textsuperscript{382D}, S\textsuperscript{468D}Nedd4-2 were capable to influence EAAT2 activity. As shown in Figure 16, both mutants failed to modulate EAAT2 (from 2.09 ± 0.89 pmol/10 min/oocyte in EAAT2-HA expressing oocytes to 1.89 ± 0.63 pmol/10 min/oocyte and 3.09 ± 1.50 pmol/10 min/oocyte in oocytes coexpressing EAAT2-HA with C\textsuperscript{962S}Nedd4-2 and S\textsuperscript{382D}, S\textsuperscript{468D}Nedd4-2 respectively, n= 22). Additional expression of S\textsuperscript{422D}SGK1 augmented the transporter activity (from 2.09 ± 0.89 pmol/10 min/oocyte in EAAT2-HA expressing oocytes to 3.01 ± 0.69 pmol/10 min/oocyte in oocytes coexpressing EAAT2-HA with S\textsuperscript{382D}, S\textsuperscript{468D}Nedd4-2 and S\textsuperscript{422D}SGK1, n= 22). Thus, the kinase stimulates EAAT2 at least by indirectly inhibiting the ubiquitin ligase Nedd4-2.
Figure 16 SGK1 promotes EAAT2-HA activity indirectly through inhibiting the ubiquitin ligase Nedd4-2. Neither the Nedd4-2 mutant mimicking its phosphorylation state by SGKs \(^{(S382D, S468D) Nedd4-2}\) nor the mutant \(^{(S422D) Nedd4-2}\) nor the mutant \(^{(S422D) Nedd4-2}\) bearing a destructed catalytic domain modify \([\text{^3}H\] – L-glutamate uptake. * indicates statistically significant difference to glutamate uptake in oocytes expressing EAAT2-HA alone n= 22.

Coexpression of SGK1 could impact EAAT2 activity and expression. To rule out the possibility that SGK1 inhibits Nedd4-2 by downregulating Nedd4-2 expression, western blots were performed. According to immunoblotting Nedd4-2 protein abundance was unaffected upon coexpression of \(^{(S422D) SGK1}\) (Figure 17). The SGK1 isoforms, SGK2-3, were also unable to modulate Nedd4-2 expression. Thus, SGKs impact Nedd4-2 activity while leaving Nedd4-2 levels unaffected.
Figure 17. SGK1-3 expression in oocytes does not affect the expression levels of Nedd4-2. The histogram depicts the quantification of the Nedd4-2 band intensities from three different western blots. All data were normalized to cells expressing EAAT2 + Nedd4-2. Arithmetic means ± SEM.

SGK1 contains a PY motif, a target structure that is recognized by Nedd4-2. Thus, Nedd4-2 could bind to and ubiquitinate the protein kinase, preparing it for degradation by the proteosome. To clarify whether Nedd4-2 downregulates SGK1 expression, the ubiquitin ligase was coinjected with SGK1 at different concentrations and SGK1 expression was analyzed by western blotting (Figure 18). SGK1 band intensities quantification demonstrated that Nedd4-2 does not significantly alter SGK1 expression.
Figure 18 SGK1 expression remains unaltered upon Nedd4-2 overexpression. Immunoblots with a specific SGK1 antibody showed that expression of the kinase is not modulated by the ubiquitin ligase Nedd4-2. The histogram depicts the quantification of the SGK1 band intensities from three different western blots. All data were normalized to cells expressing EAAT2 + SGK1. Arithmetic means ± SEM.

### 6.2 Modulation of EAAT4 by SGK1

#### 6.2.1 SGK1 enhances EAAT4 mediated glutamate transport

In order to investigate the mechanism of EAAT4 activity modulation by SGK1, EAAT4 was expressed in *Xenopus laevis* oocytes and glutamate transport measured in the presence and absence of constitutively active S422D SGK1. On the
fifth day of kinase cRNA injection, labelled L-glutamate uptake was studied as a measure of EAAT4 activity.

Tracer-flux studies revealed an increase in EAAT4 transport rate (223.132 ± 41.17 % of control, n = 18, Figure 19) upon coexpression of S422D-SGK1. Glutamate uptake into water injected oocytes was less than 42.41 ± 18.55 % of control (n= 21).

![Graph showing uptake of [3H] L-Glutamate](image)

**Figure 19** SGK1 expression in EAAT4-injected oocytes enhances the activity of EAAT4. Arithmetic means ± SEM. * indicates statistically significant difference to uptake in *Xenopus* oocytes expressing EAAT4 alone. Uptake values were normalized in each batch of oocytes to the mean value obtained in oocytes expressing EAAT4 alone. n= 21.

### 6.2.2 Disruption of the putative SGK1 phosphorylation sites (Thr40 and Thr504) on EAAT4 abrogates transporter stimulation

EAAT4 contains two putative SGK1 phosphorylation sites on its sequence at Thr40 and Thr504 present at the cytosolic amino and carboxy termini, respectively. Both sites are highly conserved among species including human, mouse and rat
and thus suggests an important role of these residues in EAAT4 function and regulation. To determine whether SGK1 modulates EAAT4 uptake by phosphorylating EAAT4 directly, threonine at positions 40 and 504 in EAAT4 were mutated into alanine (T^{40AT504A}EAAT4) by site-directed mutagenesis and its regulation evaluated upon coexpression of the kinase. Threonine replacement eliminates the putative phosphorylation site of SGK1 (Arg-Xaa-Arg-Xaa-Xaa-Ser/Thr) on EAAT4, thus hypothetically SGK1 cannot act on that site.

Xenopus oocytes were injected with wild-type EAAT4 or phosphorylation-deficient T^{40AT504A}EAAT4 alone or together with constitutively active S^{422D}SGK1. On the fifth day of injection, labelled L-glutamate uptake was studied and western blotting of whole cell lysates performed. Disruption of the putative SGK1 phosphorylation sites abrogated EAAT4 stimulation by S^{422D}SGK1 (from 77.31 ± 13.23 % of control, n = 23, in T^{40AT504A}EAAT4 expressing oocytes to 63.23 ± 10.80 % of control, n = 22, in oocytes expressing T^{40AT504A}EAAT4 along with S^{422D}SGK1), suggesting that the kinase is effective through direct EAAT4 phosphorylation (Figure 20).
Figure 20 Mutant EAAT4 (T40A,T504A-EAAT4) with disrupted SGK1 phosphorylation sites failed to be stimulated by S422D SGK1. Proper S422D SGK1 expression was checked by western blotting. Arithmetic means ± SEM. * indicates statistically significant difference to uptake in *Xenopus* oocytes expressing wild-type EAAT4 alone. Uptake values were normalized to the mean value obtained in oocytes expressing wild-type EAAT4 alone. n= 22-23.

6.2.3 Phosphorylation at Thr40 on EAAT4 is essential for transporter stimulation

To delineate whether a unique or both phosphorylation sites are required for enhanced EAAT4 activity, single phosphorylation-deficient mutants were generated. The cRNAs of wild-type EAAT4, T40A EAAT4 or T504A EAAT4 alone or together with constitutively active S422D SGK1 were expressed in *Xenopus*
Results

oocytes and on the fifth day of injection, labelled L-glutamate uptake was studied and western blotting of whole cell lysates performed. Coexpression of $S422D$SGK1 with $T504A$EAAT4 promoted the transporter’s activity (from 100.51 ± 20.91 % of control, n = 9 to 192.71 ± 26.27 % of control, n = 9), whereas expression of the kinase failed to modulate $T40A$EAAT4 function despite normal SGK1 expression levels as assessed by western blotting of whole cell lysates (Figure 21).

Figure 21 Upon coexpression of $S422D$SGK1, $T504A$EAAT4 activity is stimulated significantly while the activity of $T40A$EAAT4 remains unaltered. Western blotting confirmed proper SGK1 expression. Arithmetic means ± SEM. * indicates statistically significant difference to uptake in *Xenopus* oocytes expressing wild-type EAAT4 alone. + indicates statistically significant difference to uptake in *Xenopus* oocytes expressing $T504A$EAAT4 alone. Uptake values were normalized to the mean value obtained in oocytes expressing wild-type EAAT4 alone. n= 20.
6.2.4 Phosphorylation at Thr40 on EAAT4 is required for enhanced EAAT4 plasma membrane abundance

Further experiments were performed to pursue whether ablation of SGK1 phosphorylation sites in EAAT4 blunts the kinase effect on plasma membrane abundance. To investigate cell surface expression of wild type and EAAT4 mutants, fusion constructs containing a hemagglutinin (HA)-tag in an extracellular loop were generated by two-stage site-directed mutagenesis and expressed in *Xenopus* oocytes.

EAAT4 plasma membrane abundance examined by quantitative immunoassays revealed that the expression of the EAAT4 phosphorylation-deficient (T40A,T504A)EAAT4 mutant was unaffected by SGK1 (from 101.44 ± 11.29 % of control, n = 53, in T40A,T504A EAAT4 expressing oocytes to 104.72 ± 14.08 % of control, n = 42, in oocytes expressing T40A,T504A EAAT4 along with S422D SGK1, Figure 22). Phosphorylation at Thr40 appears to be responsible for the increased EAAT4 abundance since T504A EAAT4 expression was augmented upon expression of the kinase (from 100.00 ± 9.15 % of control, n = 36 to 186.98 ± 28.58 % of control, n = 36).
Figure 22  

S422D SGK1 coexpressed with T504A EAAT4 enhances the plasma membrane abundance of the transporter noticeably. However, the kinase does not enhance the plasma membrane abundance when coexpressed with T40AT504A EAAT4. Arithmetic means ± SEM. * indicates statistically significant difference to oocytes injected with EAAT4 or T504A EAAT4 alone. Cell surface expression was normalized in each batch of oocytes to the mean RLU (Relative Light Units) value obtained in oocytes expressing EAAT4 alone. n= 36.

6.2.5 Nedd4-2 coexpression inhibits the activity of EAAT4

Prior to study the impact of silencing endogenous Nedd4-2 on the glutamate transporter activity, Nedd4-2 and EAAT4 were expressed in Xenopus oocytes and the effect of the ubiquitin ligase on EAAT4 was analyzed.

EAAT4 cRNA alone or along with Nedd4-2 cRNA was injected in oocytes and its activity was measured on the fifth day after injection using tracer flux
measurements. Figure 23 shows the downregulation of EAAT4 activity upon Nedd4-2 expression (58.65 ± 9.97% of control, n= 20).

![Figure 23](image)

**Figure 23 Expression of the ubiquitin ligase Nedd4-2 downregulates EAAT4 activity significantly.** Arithmetic means ± SEM. * indicates statistically significant difference to uptake in *Xenopus* oocytes expressing wild-type EAAT4 alone. Uptake values were normalized to the mean value obtained in oocytes expressing wild-type EAAT4 alone. n= 20.

### 6.2.6 Silencing of intrinsic xNedd4-2 upregulates EAAT4 function

SGK1 modulates several transporters indirectly through phosphorylation and thus inhibition of the ubiquitin ligase Nedd4-2, which otherwise tags its target protein for degradation\(^ {38,60,176}\).

Since *Xenopus* oocytes possess intrinsic Nedd4-2 (xNedd4-2), SGK1 could additionally be effective through xNedd4-2 inhibition. Silencing experiments using
the RNAi sequence-specific posttranscriptional silencing technique in *Xenopus* oocytes were performed to assess whether xNedd4-2 downregulation promotes EAAT4 activity.

Oocytes were injected with EAAT4 alone or together with a double-stranded xNedd4-2 specific siRNA oligo. On the fifth day of cRNA injection, L-glutamate was measured. Functional studies showed enhanced EAAT4 activity in Nedd4-2 silenced oocytes (256.67 ± 53.38 % of control, n = 14, Figure 24).

![Western blot](image)

**Figure 24** Significant enhancement of EAAT4 activity is noticed when intrinsic xNedd4-2 is silenced in oocytes. ^S422D^SGK1 expressed along with Nedd4-2 siRNA and EAAT4 further enhances the transporters’ activity. Western blotting confirmed proper SGK1 expression. Arithmetic means ± SEM. * indicates statistically significant difference to uptake in *Xenopus* oocytes expressing wild-type EAAT4 alone. Uptake values were normalized to the mean value obtained in oocytes expressing EAAT4. n= 14.
6.2.6.1 xNedd4-2 siRNA downregulates xNedd4-2 expression

To demonstrate xNedd4-2 silencing, xNedd4-2 protein levels were analysed by western blotting. Oocytes injected with EAAT4 alone and with xNedd4-2 siRNA were lysed separately on the fifth day of injection and were analysed for Nedd4-2 expression. Western blots confirmed the significant declination of intrinsic Nedd4-2 expression.

Densitometric analysis of Nedd4-2/GAPDH ratio of band intensities revealed a reduced (by two fold) Nedd4-2 expression in oocytes injected with xNedd4-2 siRNA oligo (Figure 25).

![Western blot](image)

**Figure 25** Western blot reveals the significant declination of intrinsic xNedd4-2 abundance upon injection of Nedd4-2 siRNA. Nedd4-2/GAPDH band intensities from three independent experiments were normalized in each batch to the value of Nedd4-2/GAPDH band intensity of oocytes expressing EAAT4 alone.

6.2.6.2 xNedd4-2 siRNA does not alter GLUT1 expression

To demonstrate the specificity of the effect observed, the activity of the facilitative glucose transporter GLUT1, that was previously reported to be unaffected by Nedd4-2, was studied upon injection of xNedd4-2 siRNA oligo.
GLUT1 function was not significantly altered by the coexpression of xNedd4-2 siRNA (75.21 ± 9.65 % of control, n = 27, Figure 26).

Figure 26 Injection of xNedd4-2 siRNA does not significantly alter GLUT1 expression, thus demonstrating Nedd4-2 siRNA specificity. Arithmetic means ± SEM. Uptake values were normalized to the mean value obtained in oocytes expressing GLUT1 alone. n = 27.
7 Discussion

The present data reveals two novel modulators of the sodium dependent glutamate transporters EAAT2 and EAAT4 namely the protein kinase SGK1 and the ubiquitin ligase Nedd4-2. SGK1 upregulates EAAT2 and EAAT4, while Nedd4-2 downregulates both transporters. The EAAT2 transporter does not bear a SGK1 consensus motif. Thus, the kinase modulates the transporter through an intermediate protein. We and others have shown that SGK binds to and phosphorylates Nedd4-2 thus decreasing the affinity of the ubiquitin ligase to its target proteins. Therefore, SGK1 might be effective through phosphorylation of Nedd4-2, an assumption supported by the observation that the Nedd4-2 mutant mimicking the SGK1-phosphorylated form does not impact EAAT2 function. However, the effect of Nedd4-2 is not completely abolished by SGK1, which may indicate that SGK1 cannot completely suppress Nedd4-2 function. On the other hand, SGK1 may not exclusively be effective through phosphorylation of Nedd4-2 and additional intermediatory proteins are yet to be identified.

SGK1 enhances the carrier protein abundance. In a previous study utilizing brefeldin A, a drug interfering with the exocytotic pathway, we were able to demonstrate that SGK1 delays the clearance of transport proteins from the cell membrane. However, in the case of EAAT2, it is not known whether delayed clearance of the transporter from the membrane causes its increased cell surface abundance. Further studies are required to clarify this issue.

Nedd4-2 and SGK1 may participate in the signaling of neuroexcitability and neuroexcitotoxicity. According to the present results, Nedd4-2 would downregulate EAAT2 and thus delay the clearance of glutamate from the extracellular space. As a result the effects of glutamate may be enhanced. SGK1, on the other hand, is expected to accelerate the clearance of glutamate from the extracellular space and thus foster termination of an excitatory signal.

Enhanced expression of EAAT2 has been shown to protect against excitotoxic neuronal death and deranged function of EAAT2 has been implicated in several neuronal diseases including amyotrophic lateral sclerosis, epilepsy, and
Alzheimer disease\textsuperscript{186,187}. Moreover, lack of EAAT2 function was shown to potentiate retinal ganglion cell death\textsuperscript{188}. In axotomy or after spinal cord injury, EAAT2 has been shown to be upregulated, an effect thought to play a protective role\textsuperscript{189,190} and overexpression of EAAT2 appears to protect against motor neuron degeneration and epilepsy. During ischemia, on the other hand, a reversed mode function of EAAT1 and of EAAT2 has been postulated to enhance extracellular glutamate concentration\textsuperscript{191}. Inappropriate regulation of the carriers by Nedd4-2 and/or SGK1 could similarly participate in the pathophysiology of those diseases.

The ability of SGK1 to stimulate EAAT2 activity is also observed with the isoforms SGK2 and SGK3 and with protein kinase B. Thus, these kinases have the potential to replace SGK1 in this functional capacity. This may be one reason for the apparently mild phenotype of the SGK1-knockout mouse\textsuperscript{192}. Complete knockout of PDK1, i.e. the kinase upstream of all three SGKs and PKB, is not compatible with survival\textsuperscript{193}.

Taken together, the present study provides evidence that the serum and glucocorticoid inducible kinase isoforms SGK1, SGK2 and SGK3 and the related kinase PKB can regulate the glutamate transporter EAAT2. The kinases phosphorylate the ubiquitin ligase Nedd4-2 and thereby stimulate the activity and cell surface expression of EAAT2. The mechanism is likely to participate in the regulation of neuronal excitability.

EAAT4 bears two putative SGK1 consensus sites (Thr40 and Thr504) that are highly conserved among several species suggesting that these sites might play a role in the transporter’s function. Our data provide evidence that the kinase modulates EAAT4 activity directly and that, from both putative SGK1 phosphorylation sites, the residue Thr40 is essential for SGK1 induced stimulation of EAAT4 function and surface abundance.

SGK1 is also capable to enhance the activity of other members of the excitatory amino acid transporter family (EAAT1, EAAT3 and EAAT5)\textsuperscript{38,39,41,194}. Similarr to EAAT4, the glial transporter EAAT1 is upregulated by SGK1 in part via direct phosphorylation at a putative SGK1 consensus site (Thr482)\textsuperscript{38}. EAAT1
function was enhanced by SGK1 in the presence of S\textsuperscript{382}A, S\textsuperscript{468}A Nedd4-2, while EAAT1 expressed alone with S\textsuperscript{382}A, S\textsuperscript{468}A Nedd4-2 showed a decrease in current.

The transporters EAAT3 and EAAT5 do not contain any SGK1 phosphorylation site in its sequence and might therefore be regulated indirectly or directly at a non-SGK1 consensus site. In the present study we further show that EAAT2 expression and activity is upregulated by SGK1 through phosphorylation and thus inhibition of the ubiquitin ligase Nedd4-2\textsuperscript{194}. This mechanism of SGK1 action is shared by EAAT1 and EAAT4, according to our present results on xNedd4-2 silencing in which EAAT4 activity was augmented in oocytes injected with xNedd4-2-specific siRNA oligos.

The mechanisms by which SGK1 promotes EAAT3 and EAAT5 activity are still undefined. They might include the phosphorylation of a hitherto unknown intermediate protein since coexpression of a catalytically inactive SGK1 mutant failed to modulate the transporters\textsuperscript{41}.

Phosphorylation processes are known to modulate EAATs activity. Several growth factors that are neuroprotective enhance EAAT activities via activation of kinases: insulin-like growth factor-1 (IGF-1), epidermal growth factor receptor (EGFR) agonists and platelet-derived growth factor (PDGF) upregulate EAAT1, EAAT2 and EAAT3 respectively via phosphatidylinositol 3 kinase (PI3K) as demonstrated by PI3K inhibitors and constitutively active PI3K constructs\textsuperscript{195-197}. Since SGK1 is activated by PI3K, the kinase might be the downstream effector in the PI3K signalling pathway activated by those growth factors.

Besides, SGK1 itself is stimulated at gene transcriptional level by agonists such as mineralocorticoids\textsuperscript{4-6}, follicle stimulating hormone (FSH)\textsuperscript{7,8}, transforming growth factor β (TGF-β)\textsuperscript{9,10}, and thrombin\textsuperscript{11}. Stimulation of SGK1 may lead to the enhancement of other ion channels and transporters where SGK1 is localized. For instance, cerebellar SGK1 expression was enhanced in the cerebellar Purkinje cells of mice grown under dehydration condition, where EAAT4 predominantly express\textsuperscript{40}. Accordingly SGK1 has the possibility to stimulate the EAAT4 activity in Purkinje cells under such stress conditions.
EAATs contain at least two putative phosphorylation sites for PKC and one for PKA\textsuperscript{198}. Several reports have shown PKC and PKA modulation of glutamate transporters\textsuperscript{170,199-202}. Activation of PKC enhances GLT1 (EAAT2) in Hela transfected cells and EAAC1 (EAAT3) in C6 Glioma cells\textsuperscript{170,199}, whereas decreases GLAST activity in Bergmann glial cells\textsuperscript{147,148}.

Similar to SGK1, PKC modulates EAATs through different mechanisms: directly as a result of transporter phosphorylation at a putative PKC phosphorylation site (i.e. Ser113 on GLT1 sequence)\textsuperscript{170} or indirectly through phosphorylation of intermediate proteins\textsuperscript{147}. In contrast to SGK1, PKC modulates several EAATs by enhancing the transporter catalytical activity without altering its surface abundance\textsuperscript{170}.

In contrary to SGK1, Nedd4-2 was known to downregulate all members of the excitatory amino acid transporter family except for EAAT5\textsuperscript{41,203}. SGK1 expressed along with Nedd4-2 and the EAATs (EAAT1-4) inhibited the downregulating property of Nedd4-2 and additionally enhanced EAAT1-4 activity\textsuperscript{38-41,194,203}.

In summary, the results presented here indicate that SGK1 modulates EAAT4 function and plasma membrane abundance via direct phosphorylation of the transporter. The residue Thr40 within the SGK1 consensus site present in EAAT4 is essential for the SGK1 stimulatory effects. SGK1 might additionally be effective through phosphorylation and thus inhibition of intrinsic ubiquitin ligase Nedd4-2 as suggested by our silencing experiments. Understanding the signalling mechanisms regulating EAAT4 may have significant implications for developing novel drugs to limit neuroexcitotoxicity.
8 References


References


References


Acknowledgement

First of all, I would like to thank my Ph D advisor Prof. Dr. Med. Florian Lang for giving me this great opportunity to work under his guidance. I am also grateful to his support and encouragement to enlighten my career.

I would like to utilize this moment to show my gratitude to my Ph D supervisor Privatdozent Dr. rer. nat. Monica Palmada for her invaluable guidance and constant encouragement in my research works.

I am particularly indebted to Privatdozent Dr. rer. nat. Christoph Böhmer for teaching electrophysiology, providing good working-environment and guiding in laboratory organization.

I am very grateful to Ms. Brigitte Noll and Ms. Annunziata Fragasso for their technical assistance.

I want to thank my friends Azeemudeen Husain, Leenus Martin, Prakash Mohan Peranandam, Ravisankar Kasinathan and Sankarganesh Jeyaraj for their encouragement, support and suggestions.

Finally I would like to thank all other colleagues of Physiology Institute for making the institute, a good place to work with.
Curriculum Vitae

Jeyaganesh Rajamanickam

Personal Data

Date of Birth 1979/06/11
Place of Birth Madurai, India
Sex Male
Nationality Indian
Marital Status Single
e-mail jeyaganesh.rajamanickam@gmail.com
Phone +49 (0)174 1636423

Work Address Institute for Physiology I
Gmelinstrasse 5
72076 Tuebingen
Germany

Academic training

2003-present  PhD work
Eberhard-Karls University of Tuebingen, Germany
“The serum and glucocorticoid inducible kinase in the regulation of sodium coupled amino acid transporters”
Prospective examination date: January 2007

April 2002  M. Sc.
Microbiology, Bharathidasan University, Trichy, TN, India:
“Identification of integral membrane protein genes from a cDNA library of Aspergillus fumigatus”

April 2000  B. Sc.
Microbiology. Madurai Kamaraj University Madurai, TN, India
Methodological expertise

- **Molecular Biology / Biochemistry**

  Heterologous protein expression in *Xenopus laevis* oocytes

  Site-directed mutagenesis

  *In vitro* transcription / translation

  Generation and screening of cDNA libraries.

  Generation of recombinant proteins

  Cell surface expression analysis of membrane proteins by biotinylation and chemiluminescence

  Gene silencing by RNA interference

  Detection of protein phosphorylation by immunoprecipitation / immunoblotting and *in vitro* kinase assays

  PCR-based techniques for cloning and sequencing, stable and transient expression of membrane proteins in *Xenopus laevis* oocytes

- **Functional Methods**

  Animal care and surgery of *Xenopus laevis* oocytes

  Heterologous expression and functional characterization of recombinant proteins in *Xenopus laevis* oocytes

  Radiolabeled tracer flux measurements

  Two electrode voltage-clamp

- **Basic microbiological techniques**

Publications (peer review)


---

**References**

**Prof. Dr. med. Florian Lang**

Chairman
Institute of Physiology I
Eberhard-Karls University of Tuebingen
Gmelinstrasse 5
72076 Tuebingen
Germany
Phone +49 (0)7071 29-72194
FAX +49 (0)7071 29-3073
e-mail: florian.lang@uni-tuebingen.de
Privatdozent Dr. rer. nat. Christoph Böhmer
Associate Professor
Institute of Physiology I
Eberhard-Karls University of Tuebingen
Gmelinstrasse 5
72076 Tuebingen
Germany
Phone +49 (0)7071 29-73071
FAX +49 (0)7071 29-3073
e-mail: christoph.boehmer@uni-tuebingen.de

Privatdozent Dr. rer. nat. Monica Palmada
Associate Professor
Institute of Physiology I
Eberhard-Karls University of Tuebingen
Gmelinstrasse 5
72076 Tuebingen
Germany
Phone +49 (0)7071 29-76890
FAX +49 (0)7071 29-3073
e-mail: monica.palmada@uni-tuebingen.de